var title_f13_53_14160="Literacy by education";
var content_f13_53_14160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Percentage of adults in each health literacy level, by highest educational attainment: 2003",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 617px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Detail may not sum to totals because of rounding. Adults are age and older living in households or prisons. Adults who could not language spoken or cognitive or mental disabilities (3 percent in 2003).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Accessed at: National Center for Education Statistics. file://nces.ed.gov/naal/health_ results.asp. US Department of Education, Institute of Education Sciences, Education Statistics, 2003 National Assessment of Adult Literacy.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14160=[""].join("\n");
var outline_f13_53_14160=null;
var title_f13_53_14161="Stage 2 prolapse";
var content_f13_53_14161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Stage II prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increased distal abdominal pressure on a damaged perineal body may result in severe rectocele and perineal descent (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14161=[""].join("\n");
var outline_f13_53_14161=null;
var title_f13_53_14162="Patient information: Abdominal wall hernias (The Basics)";
var content_f13_53_14162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87022\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/2/3105\">",
"         Abdominal wall hernias",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/6/23648\">",
"          Intestines bulging through hernia",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/6/2146\">",
"         Patient information: Congenital hernia of the diaphragm (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/44/42689\">",
"         Patient information: Groin (inguinal) hernias in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/33/37393\">",
"         Patient information: Hiatal hernia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/62/42977\">",
"         Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/39/6770\">",
"         Patient information: Small bowel obstruction (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Abdominal wall hernias (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3743941\">",
"      <span class=\"h1\">",
"       What is an abdominal wall hernia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your internal organs and tissues are held in place by a tough outer wall of tissue called the &ldquo;abdominal wall.&rdquo; An abdominal hernia is an area in that wall that is weak or torn. Often when there is a hernia, organs or tissues that are normally held in place by the abdominal wall bulge or stick out through the weak or torn spot.",
"     </p>",
"     <p>",
"      There are many different kinds of abdominal wall hernias. These are shown in the Figure (",
"      <a class=\"graphic graphic_figure graphicRef87588 \" href=\"UTD.htm?3/2/3105\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3743958\">",
"      <span class=\"h1\">",
"       What are the symptoms of abdominal wall hernias?",
"      </span>",
"      &nbsp;&mdash;&nbsp;These hernias do not always cause symptoms. When they do, they can cause some or all of these symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A bulge somewhere on the trunk of the body &ndash; This bulge can be so small that you don&rsquo;t even realize it&rsquo;s there.",
"       </li>",
"       <li>",
"        Pain, especially when coughing or using or straining nearby muscles",
"       </li>",
"       <li>",
"        A pulling sensation around the bulge",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Abdominal wall hernias can balloon out and form a sac. That sac can end up holding a loop of intestine or a piece of fat that should normally be tucked inside the belly. This can be painful and even dangerous if the tissue in the hernia gets trapped and unable to slide back into the belly. When this happens, the tissue does not get enough blood, so it can become swollen or even die (",
"      <a class=\"graphic graphic_figure graphicRef76003 \" href=\"UTD.htm?23/6/23648\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3743990\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. See a doctor or nurse if you have any of the symptoms of a hernia. In most cases, doctors can diagnose a hernia just by doing an exam. During the exam, the doctor might ask you to cough or bear down while pressing on your hernia. This might be uncomfortable, but it is necessary to find the source of the problem.",
"     </p>",
"     <p>",
"      Most of the time, the contents of the hernia can be &ldquo;reduced,&rdquo; or gently pushed back into the belly. Still, there are times when the hernia gets trapped and won&rsquo;t go back in. If that happens, the tissue that is trapped can get damaged.",
"     </p>",
"     <p>",
"      If you develop pain around a hernia bulge or feel sick, call your doctor or surgeon right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3744005\">",
"      <span class=\"h1\">",
"       How are hernias treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not all hernias need treatment right away. But many do need to be repaired with surgery. Surgeons can repair most hernias in 1 of 2 ways. The right surgery for you will depend on the size of your hernia, where on the abdominal wall it is, whether this is the first time it is getting repaired, and what your general health is like. The 2 types of surgery are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Open surgery &ndash; During an open surgery, the surgeon makes an incision near the hernia. Then he or she looks at the tissue that is stuck in the hernia, and if it is healthy, gently pushes it back into place. Sometimes a small piece of tissue needs to be removed. Next, the surgeon sews the layers of the abdominal wall back together, so that nothing can bulge through. In some cases, surgeons will also patch the area with a piece of mesh. The mesh takes some of the strain off the abdominal wall. That way the hernia is less likely to happen again.",
"       </li>",
"       <li>",
"        Laparoscopic surgery &ndash; During laparoscopic surgery, the surgeon makes a few incisions that are much smaller than those used in open surgery. Then he or she inserts long thin tools into the area near the hernia. One of the tools has a camera (called a &ldquo;laparoscope&rdquo;) on the end, which sends pictures to a TV screen. The surgeon can look at the picture on the screen to guide his or her movements. Then he or she uses the long tools to repair the hernia either with stitches alone or with mesh.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your hernia has reduced the blood supply to a loop of intestine, your doctor might need to remove that piece of intestine and sew the 2 ends back together.",
"     </p>",
"     <p>",
"      The recovery and aftercare for each type of hernia repair is different. Your doctor or nurse can tell you what to expect after your surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3744038\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/62/42977?source=see_link\">",
"       Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/44/42689?source=see_link\">",
"       Patient information: Groin (inguinal) hernias in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2146?source=see_link\">",
"       Patient information: Congenital hernia of the diaphragm (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/33/37393?source=see_link\">",
"       Patient information: Hiatal hernia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/39/6770?source=see_link\">",
"       Patient information: Small bowel obstruction (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/53/14162?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87022 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14162=[""].join("\n");
var outline_f13_53_14162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3743941\">",
"      What is an abdominal wall hernia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3743958\">",
"      What are the symptoms of abdominal wall hernias?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3743990\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3744005\">",
"      How are hernias treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3744038\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87022\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/2/3105\">",
"      Abdominal wall hernias",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/6/23648\">",
"       Intestines bulging through hernia",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2146?source=related_link\">",
"      Patient information: Congenital hernia of the diaphragm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/44/42689?source=related_link\">",
"      Patient information: Groin (inguinal) hernias in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/33/37393?source=related_link\">",
"      Patient information: Hiatal hernia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/62/42977?source=related_link\">",
"      Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/39/6770?source=related_link\">",
"      Patient information: Small bowel obstruction (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_53_14163="Donovanosis";
var content_f13_53_14163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Donovanosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous ulcerogranulomatous, friable lesions are visible in the inguinal area and on the scrotum in a patient with donovanosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr.; The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14163=[""].join("\n");
var outline_f13_53_14163=null;
var title_f13_53_14164="Inside out signl integr";
var content_f13_53_14164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Inside-out integrin activation pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chemokines bind to their G protein-coupled receptors (GPCRs) on leukocytes, triggering a series of intracellular signals, which lead to the activation of Rap1 (repressor activator protein 1). Rap1 is crucial for integrin activation. In order to assure anchorage to the cytoskeleton and optimal integrin activation, Talin and Kindlin 3 must bind to the beta subunit of the integrin. Activated integrins have a fully extended, high-affinity structure, with an open ligand binding site.",
"    <div class=\"footnotes\">",
"     GPCR: G protein coupled receptors; CalDAG GEFs: Diacylglycerol guanine nucleotide exchange factor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14164=[""].join("\n");
var outline_f13_53_14164=null;
var title_f13_53_14165="Capecitabine: Patient drug information";
var content_f13_53_14165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Capecitabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     see \"Capecitabine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xeloda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xeloda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, you must have your blood work checked often. This drug could cause a bleeding problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to capecitabine, fluorouracil (5-FU), or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a dihydropyrimidine dehydrogenase (DPD) deficiency or kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699092",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the feet or hands.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698295",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain and irritation of feet or hands.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695844",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696357",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your dose may be changed if you have side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11667 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14165=[""].join("\n");
var outline_f13_53_14165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145140\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021284\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021286\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021285\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021290\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021291\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021293\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021288\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021289\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021294\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021295\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=related_link\">",
"      Capecitabine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_53_14166="Epidemiology, microbiology, and pathogenesis of tularemia";
var content_f13_53_14166=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, microbiology, and pathogenesis of tularemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14166/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14166/contributors\">",
"     Robert L Penn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14166/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14166/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14166/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14166/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14166/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/53/14166/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H274969625\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tularemia is the zoonotic infection caused by Francisella tularensis, an aerobic and fastidious gram-negative bacterium. Human infection occurs following contact with infected animals or invertebrate vectors. Synonyms include Francis' disease, deer-fly fever, rabbit fever, water-rat trappers' disease, wild hare disease (yato-byo), and Ohara's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, microbiology, and pathogenesis of infection due to F. tularensis will be reviewed here. The clinical manifestations, diagnosis, treatment, and prevention of tularemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29154667\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of infections in humans and animals are caused by F. tularensis subspecies tularensis (the more virulent species) and F. tularensis subspecies holarctica. Human disease is rarely associated with the subspecies novicida and F. philomiragia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In North America, F. tularensis has been described in the United States, Canada, and Mexico. In the United States, the majority of cases have occurred in Arkansas, Missouri, South Dakota, and Oklahoma (",
"    <a class=\"graphic graphic_figure graphicRef68457 \" href=\"UTD.htm?36/47/37622\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2010, two-thirds of the reported cases were in Arkansas, Missouri, Kansas, South Dakota, Oklahoma, and California (",
"    <a class=\"graphic graphic_figure graphicRef65498 \" href=\"UTD.htm?38/18/39205\">",
"     figure 2",
"    </a>",
"    ). Other countries known to have endemic tularemia include most European countries, the former Soviet Union, Tunisia, Turkey, Israel, Iran, China, and Japan. Tularemia is relatively uncommon in African countries, Australia, England, and South American countries.",
"   </p>",
"   <p>",
"    F. tularensis subspecies tularensis accounts for approximately 90 percent of human infections in North America. In other parts of the world, F. tularensis subspecies holarctica is the more common cause of infection. Specific strains of F. tularensis subspecies tularensis may be relatively restricted in their locations, although subspecies holarctica strains are more geographically dispersed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/3\">",
"     3",
"    </a>",
"    ]. Within a single region, animal and human outbreaks may involve multiple F. tularensis types [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The organism infects more than 100 species of wild and domestic vertebrates and over 100 species of invertebrates. In the United States, important mammals include lagomorphs and rodents, such as rabbits, beavers, muskrats, squirrels, and voles. In Europe, important mammals include hares, hamsters, mice, and voles. Animals vary in their susceptibility and response to infection. Some lagomorphs and rodents, such as rabbits, tend to develop a fatal illness when infected, while many other species develop infection but do not succumb to the illness.",
"   </p>",
"   <p>",
"    Francisella is hardy in nature (though it can be difficult to isolate in the laboratory). The organism can persist in animal carcasses, mud, or water for several weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29154715\">",
"    <span class=\"h2\">",
"     Human infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans may acquire infection by several routes and manifest a variety of clinical syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transmission to humans occurs from contact with a contaminated animal or a biting insect. Overall, tick exposure during the summer months is the most commonly recognized mode of transmission in the United States, particularly in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/2\">",
"     2",
"    </a>",
"    ]. Other insect vectors include mosquitoes, horse flies, fleas, and lice [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/5\">",
"     5",
"    </a>",
"    ]. In California, Nevada, and Utah, biting flies are the predominant insect vectors, while, in areas east of these states, ticks are the predominant vectors. In Finland, Sweden, and areas of the former Soviet Union, mosquitoes are the important insect vectors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/6\">",
"     6",
"    </a>",
"    ]. F. tularensis is passed transovarially in ticks, allowing persistence in nature without the need for an infected-animal reservoir.",
"   </p>",
"   <p>",
"    Transmission of human infection also can occur from handling infected animals, splashing infected material into the eyes, or rubbing the eyes with contaminated fingers. The trade in wild animals as pets is another potential source [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/7\">",
"     7",
"    </a>",
"    ]. Carnivores, such as domestic cats and, in at least one instance, a bird, may transmit tularemia through carriage of the organism on claws or in the mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contaminated meat and water remain important environmental sources for transmission, and the disruptions caused by natural disasters or wars have been associated with tularemia outbreaks caused by the ingestion of contaminated food and water. Survival of F. tularensis in water can be prolonged, even if the water is brackish or frozen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Perhaps important to its persistence in water is the ability of the organism to multiply within Acanthamoeba castellanii, to induce encystation, and to survive within amoebal cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission can occur from airborne spread of contaminated materials, including dust, hay, and water. Airborne transmission was the suspected source of an outbreak of pneumonic tularemia in 2000 on Martha's Vineyard, Massachusetts; lawn mowing or cutting brush were risk factors for acquiring the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/11\">",
"     11",
"    </a>",
"    ]. Francisella tularensis has been identified as a category A bioterrorism agent by the Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/12\">",
"     12",
"    </a>",
"    ]. A weapon using airborne F. tularensis would most likely result in an outbreak of inhalational tularemia three to five days later, marked by an acute, undifferentiated febrile illness with predominant manifestations of pneumonia, pleuritis, and hilar lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/13\">",
"     13",
"    </a>",
"    ]. Other clinical forms of tularemia would also occur, including typhoidal, pharyngeal, and ocular tularemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clustered cases occurring without the expected epidemiologic exposures to animals, insects, or environmental activities should raise the possibility of a bioterrorism event. Specific epidemiological, clinical, and microbiological clues should lead to early suspicion of intentional tularemia and rapid activation of the health alert system, since laboratory confirmation of the agent could be delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274969632\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two species in the Francisella genus, F. tularensis and F. philomiragia. The subspecies of F. tularensis are F. tularensis subspecies tularensis (also called F. tularensis type A or F. neoarctica), F. tularensis subspecies holarctica (also called F. tularensis type B), F. tularensis subspecies novicida, and F. tularensis subspecies mediasiatica [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. In addition, molecular typing methods have identified distinct clades or genotypes of F. tularensis subspecies tularensis that differ in their geographic locations and virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Francisella spp are small, pale-staining, slow-growing, aerobic, gram-negative coccobacilli. Growth in the laboratory is optimal at 35&deg; C, with or without carbon dioxide supplementation. The organisms are fastidious and infrequently isolated from clinical specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/14\">",
"     14",
"    </a>",
"    ]. Most strains require cysteine or cystine for growth, but strains that are less fastidious or lack a cysteine requirement have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/15\">",
"     15",
"    </a>",
"    ]. F. tularensis grows on some commercial media, including chocolate agar, modified Thayer-Martin media, and buffered charcoal-yeast extract agar [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/14\">",
"     14",
"    </a>",
"    ]. Isolates suspicious for F. tularensis can be characterized as tiny, poorly-staining, gram-negative coccobacilli that are slow growing, do not grow on routine gram-negative selective media, are oxidase negative, weakly catalase positive, beta-lactamase positive, urease negative, and satellite or XV test negative [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because F. tularensis is difficult to grow and dangerous to handle, laboratory personnel should be notified whenever tularemia is considered. Routine specimens may be processed in the clinical laboratory using Biosafety Level 2 precautions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/17\">",
"     17",
"    </a>",
"    ]. However, any isolate suspected of being F. tularensis should be handled using Biosafety Level 3 precautions, and immediately referred to the state public health laboratory or another appropriate Laboratory Response Network facility for further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/17\">",
"     17",
"    </a>",
"    ]. In particular, automated identification systems should not be used because they may generate aerosols and misidentify F. tularensis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/16\">",
"     16",
"    </a>",
"    ]. Possession and shipment of F. tularensis is tightly restricted because of its potential as a bioterrorism agent, and appropriate federal regulations must be followed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274969639\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of infection with F. tularensis and its virulence factors have been the subject of intense investigation, in part because of the organism&rsquo;s potential use as an agent of bioterrorism. F. tularensis is a highly virulent organism; only 10 to 50 intradermal or inhaled organisms are required to produce clinical illness. F. tularensis subspecies tularensis (type A) in general causes a more severe clinical infection than subspecies holarctica (type B). Subspecies tularensis genotype A1b strains are more likely to be associated with invasive infections and have a higher mortality than type A1a, A2, or B strains [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After multiplying at the site of inoculation, F. tularensis spreads first to regional lymph nodes and may then spread systemically through a lymphohematogenous route. At sites of inoculation, there is an acute inflammatory reaction involving neutrophils, macrophages, and lymphocytes that results in tissue necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/18\">",
"     18",
"    </a>",
"    ]. Granulomas may form and occasionally caseate, mimicking tuberculosis. Despite this host reaction, F. tularensis may remain alive in tissues for some time.",
"   </p>",
"   <p>",
"    F. tularensis is a facultative intracellular pathogen that replicates primarily within host macrophages, but may also infect many other cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Macrophage uptake of F. tularensis is a unique process called &ldquo;looping phagocytosis&rdquo; that involves asymmetric and spacious pseudopod loops [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/22\">",
"     22",
"    </a>",
"    ]. Entry into macrophages is dependent upon complement and complement receptors; alternative pathways involve mannose receptors and class A scavenger receptors. After being taken up, phagosome maturation and phagosome-lysosome fusion are impaired, and F. tularensis quickly escapes into the cytosol. Francisella multiply in the cytosol, induce macrophage cell death, and are released to further spread the infection. Similar events occur in neutrophils. After phagocytosis, human neutrophils are unable to kill F. tularensis; the organism inhibits NADPH oxidase, the oxidative burst is suppressed, and the organism escapes into the cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In a mouse model of F. tularensis infection, most organisms recovered from blood were not in leukocytes but, rather, free in plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/25\">",
"     25",
"    </a>",
"    ]. This was independent of the inoculum size, virulence, or route of administration. The organisms grew well in whole blood but not in plasma, suggesting a requirement for host cells. These observations suggest that F. tularensis in the blood may be taken up by leukocytes where it replicates, and then escapes into the plasma where it can begin a cycle of reinfection. It has also been shown that F. tularensis can infect erythrocytes and persist within them. In addition, intraerythrocytic organisms are protected from killing by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , perhaps contributing to relapse after inadequate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An early, innate host response functions to contain infection prior to the development of acquired immunity, but is not sufficient to clear the infection. Within the macrophage cytosol, organisms activate a host-protective multimolecular complex, the inflammasome, leading to the release of proinflammatory cytokines (interleukin-1 beta and interleukin-18) that trigger caspase-1 dependent cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/27\">",
"     27",
"    </a>",
"    ]. These effects require type I interferon signaling. Other mechanisms involved in the innate immune response include neutrophils, macrophages, dendritic cells, NK cells, lymphocytes, interleukin-12, tumor necrosis factor-&alpha;, &gamma;-interferon, and Toll-like receptor 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/20\">",
"     20",
"    </a>",
"    ]. Natural antibody responses to carbohydrate antigens occur after the development of cellular immunity, and are insufficient to protect against infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast, recovery from infection is dependent upon the development of cell-mediated immunity. Cell-mediated immunity is directed against protein antigens, and is dependent upon CD4",
"    <sup>",
"     +",
"    </sup>",
"    and CD8",
"    <sup>",
"     +",
"    </sup>",
"    T-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. As a consequence, macrophages are activated to kill intracellular F. tularensis through a process that involves tumor necrosis factor-&alpha;, &gamma;-interferon and the production of reactive nitrogen products [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The virulence of F. tularensis has been correlated with several of its phenotypic characteristics, including encapsulation, LPS, pili, and production of acid phosphatases and a siderophore [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/20,30\">",
"     20,30",
"    </a>",
"    ]. Subsequently, genomic studies have identified specific genetic correlates of virulence, including a cluster of genes known as the Francisella pathogenicity island (FPI) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14166/abstract/20\">",
"     20",
"    </a>",
"    ]. Many of the FPI genes are involved in animal virulence and intracellular survival, and are induced by intracellular growth of the organism. &nbsp;FPI genes are under transcriptional regulation including by environmental factors, including exposure to iron and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274969660\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tularemia is a zoonotic infection caused by the gram-negative bacterium Francisella tularensis. Human infection occurs following contact with infected animals or invertebrate vectors. (See",
"      <a class=\"local\" href=\"#H274969625\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, the majority of cases in 2010 occurred in Arkansas, Missouri, Kansas, South Dakota, Oklahoma, and California. Other countries known to have endemic tularemia include Canada, Mexico, most European countries, the former Soviet Union, Tunisia, Turkey, Israel, Iran, China, and Japan. (See",
"      <a class=\"local\" href=\"#H29154667\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Francisella tularensis infects more than 100 species of wild and domestic vertebrates and over 100 species of invertebrates. Insect vectors include ticks, mosquitoes, horse flies, fleas, and lice. Rodents and lagomorphs, such as rabbits, tend to develop a fatal illness when infected, while many other species develop infection but do not succumb to the illness. The organism may survive in animal carcasses, mud, and water for several weeks. (See",
"      <a class=\"local\" href=\"#H29154667\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmission of infection to humans can occur from invertebrate vectors, handling infected animals, ingesting contaminated foods, drinking contaminated water, and animal bites or scratches. Transmission also can be due to splashing infected material into the eyes, or rubbing the eyes with contaminated fingers. (See",
"      <a class=\"local\" href=\"#H29154715\">",
"       'Human infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vector-borne disease (especially by ticks, but also by flies) has become the most common mode of transmission in the United States. In some European countries, mosquito-borne disease predominates. Transmission also can occur from airborne spread of contaminated materials, including dust, hay, and water. (See",
"      <a class=\"local\" href=\"#H29154715\">",
"       'Human infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Francisella tularensis has been identified as a category A bioterrorism agent by the Centers for Disease Control and Prevention. A weapon using airborne F. tularensis would most likely result in an outbreak of inhalational tularemia three to five days later, marked by an acute, undifferentiated febrile illness with predominant manifestations of pneumonia, pleuritis, and hilar lymphadenopathy. Clustered cases occurring without the expected epidemiologic exposures to animals, insects, or environmental activities should suggest the possibility of a bioterrorism event. (See",
"      <a class=\"local\" href=\"#H29154715\">",
"       'Human infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      F. tularensis is difficult to grow and dangerous to handle; therefore, laboratory personnel should be notified whenever tularemia is considered or suspected. (See",
"      <a class=\"local\" href=\"#H274969632\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      F. tularensis is a facultative intracellular pathogen that replicates primarily within host macrophages by impairing phagosome maturation and phagosome-lysosome fusion. Recovery from infection depends on development of host cell mediated immunity (See",
"      <a class=\"local\" href=\"#H274969639\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Penn RL. Francisella tularensis (Tularemia). In: Principles and Practice of Infectious Diseases, 7th Ed, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone, Philadelphia 2010. p.2927.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Tularemia - Missouri, 2000-2007. MMWR Morb Mortal Wkly Rep 2009; 58:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/3\">",
"      Kugeler KJ, Mead PS, Janusz AM, et al. Molecular Epidemiology of Francisella tularensis in the United States. Clin Infect Dis 2009; 48:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/4\">",
"      Petersen JM, Carlson JK, Dietrich G, et al. Multiple Francisella tularensis subspecies and clades, tularemia outbreak, Utah. Emerg Infect Dis 2008; 14:1928.",
"     </a>",
"    </li>",
"    <li>",
"     Acha PN, Szyfres B. Tularemia. In: Zoonosis and Communicable Disease Common to Man and Animals, Pan American Health Organization, Washington DC 2001. Vol 1, p.275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/6\">",
"      Ryd&eacute;n P, Bj&ouml;rk R, Sch&auml;fer ML, et al. Outbreaks of tularemia in a boreal forest region depends on mosquito prevalence. J Infect Dis 2012; 205:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of tularemia among commercially distributed prairie dogs, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:688, 699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/8\">",
"      Padeshki PI, Ivanov IN, Popov B, Kantardjiev TV. The role of birds in dissemination of Francisella tularensis: first direct molecular evidence for bird-to-human transmission. Epidemiol Infect 2010; 138:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/9\">",
"      Berrada ZL, Telford Iii SR. Survival of Francisella tularensis Type A in brackish-water. Arch Microbiol 2011; 193:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/10\">",
"      El-Etr SH, Margolis JJ, Monack D, et al. Francisella tularensis type A strains cause the rapid encystment of Acanthamoeba castellanii and survive in amoebal cysts for three weeks postinfection. Appl Environ Microbiol 2009; 75:7488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/11\">",
"      Feldman KA, Enscore RE, Lathrop SL, et al. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med 2001; 345:1601.",
"     </a>",
"    </li>",
"    <li>",
"     Hodges LS, Penn RL. Francisella tularensis (Tularemia) as an agent of tularemia. In: Principles and Practice of Infectious Diseases, 7th Ed, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone, Philadelphia 2010. p.3971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/13\">",
"      Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763.",
"     </a>",
"    </li>",
"    <li>",
"     Lindquist D, Chu MC, Probert WS. Francisella and Brucella. In: Manual of Clinical Microbiology, Murray PR, Baron EJ, Jorgensen JH, et al.  (Eds), American Society for Microbiology Press, Washington DC 2007. Vol 1, p.815.",
"    </li>",
"    <li>",
"     Sj&ouml;stedt AB. Francisella. In: Bergey's Manual of Systematic Bacteriology, 2nd ed, Brenner DJ, Krieg NR, Staley JT.  (Eds), Springer-Verlag, New York 2005. Vol 2, p.200.",
"    </li>",
"    <li>",
"     CDC, ASM, APHL. Sentinel level clinical microbiology laboratory guidelines for suspected agents of bioterrorism and emerging infectious diseases: Francisella tularensis. file://www.asm.org/images/pdf/Clinical/Protocols/tularemia.pdf. (Accessed on August 05, 2011).",
"    </li>",
"    <li>",
"     Summary of laboratory biosafety level criteria file://www.cdc.gov/biosafety/publications/bmbl5/BMBL5_sect_IV.pdf (Accessed on August 09, 2011).",
"    </li>",
"    <li>",
"     Geyer SJ, Burkey A, Chandler FW. Tularemia. In: Pathology of Infectious Diseases, Connor DH.  (Ed), Appleton &amp; Lange, Stamford, Conn 1997. p.869.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/19\">",
"      Clemens DL, Horwitz MA. Uptake and intracellular fate of Francisella tularensis in human macrophages. Ann N Y Acad Sci 2007; 1105:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/20\">",
"      Pechous RD, McCarthy TR, Zahrt TC. Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development. Microbiol Mol Biol Rev 2009; 73:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/21\">",
"      Santic M, Al-Khodor S, Abu Kwaik Y. Cell biology and molecular ecology of Francisella tularensis. Cell Microbiol 2010; 12:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/22\">",
"      Clemens DL, Lee BY, Horwitz MA. Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect Immun 2005; 73:5892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/23\">",
"      McCaffrey RL, Allen LA. Francisella tularensis LVS evades killing by human neutrophils via inhibition of the respiratory burst and phagosome escape. J Leukoc Biol 2006; 80:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/24\">",
"      Oviedo-Orta E, Perreau M, Evans WH, Potolicchio I. Control of the proliferation of activated CD4+ T cells by connexins. J Leukoc Biol 2010; 88:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/25\">",
"      Forestal CA, Malik M, Catlett SV, et al. Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis 2007; 196:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/26\">",
"      Horzempa J, O'Dee DM, Stolz DB, et al. Invasion of erythrocytes by Francisella tularensis. J Infect Dis 2011; 204:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/27\">",
"      Henry T, Brotcke A, Weiss DS, et al. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J Exp Med 2007; 204:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/28\">",
"      Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 2007; 179:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/29\">",
"      Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 2007; 1105:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14166/abstract/30\">",
"      Forslund AL, Salomonsson EN, Golovliov I, et al. The type IV pilin, PilA, is required for full virulence of Francisella tularensis subspecies tularensis. BMC Microbiol 2010; 10:227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3130 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14166=[""].join("\n");
var outline_f13_53_14166=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H274969660\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274969625\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29154667\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29154715\">",
"      Human infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274969632\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274969639\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274969660\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3130\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3130|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/47/37622\" title=\"figure 1\">",
"      Reported cases of tularemia in US from 1990-2000",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/18/39205\" title=\"figure 2\">",
"      Reported cases of tularemia in US in 2010",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_53_14167="Transthoracic echocardiography: Normal cardiac anatomy and tomographic views";
var content_f13_53_14167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transthoracic echocardiography: Normal cardiac anatomy and tomographic views",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14167/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14167/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14167/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14167/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/53/14167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transthoracic echocardiography (TTE) is the primary noninvasive imaging modality for quantitative and qualitative evaluation of cardiac anatomy and function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Two-dimensional (2D) Echocardiography provides tomographic or \"thin slice\" imaging. Comprehensive echocardiographic examination typically involves imaging the heart from multiple \"viewing\" orientations. A three-dimensional appreciation of cardiac anatomy is needed to integrate 2D (and M mode) echocardiographic information.",
"   </p>",
"   <p>",
"    Echocardiographs equipped with three-dimensional capability have been developed to overcome the disadvantages of tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. These devices generally acquire a volumetric data set which can then be displayed in custom orientations. The specific clinical advantages of three-dimensional echocardiography are being defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=see_link\">",
"     \"Three-dimensional echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nomenclature, standard protocol, and normal views associated with transthoracic echocardiography are reviewed here. The instrumentation and physics associated with echocardiography, along with discussions of various echocardiographic techniques, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=see_link\">",
"     \"Echocardiography essentials: Physics and instrumentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=see_link\">",
"     \"Principles of Doppler echocardiography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=see_link\">",
"     \"Tissue Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each tomographic view is defined by the transducer position (parasternal, apical, subcostal, suprasternal) and view (long axis, short axis, 4 chamber, 5 chamber). Transducer position is altered by placing the transducer at various locations on the thorax, while the view is manipulated by a combination of angulation and rotation. Due to limitations imposed by the thoracic skeleton and lungs, not all permutations of both variables result in clinically useful images.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Orientation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While acceptance is not universal, most labs follow the recommendations of the American Society of Echocardiography with respect to image display. With this convention, the transducer position is depicted at the top of the screen, with anatomy more distant from the transducer depicted at progressively lower regions of the display, the",
"    <span class=\"nowrap\">",
"     lateral/left",
"    </span>",
"    structures to the right, and",
"    <span class=\"nowrap\">",
"     medial/right",
"    </span>",
"    structures to the left. A linear calibration scale is provided for all 2-D and M-mode measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tomographic views",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several tomographic views are commonly used (",
"    <a class=\"graphic graphic_table graphicRef51250 graphicRef60909 \" href=\"UTD.htm?29/39/30332\">",
"     table 1A-B",
"    </a>",
"    ). In 2002, a scientific statement from the American Heart Association published recommendations for standardized myocardial segmentation and nomenclature (",
"    <a class=\"graphic graphic_figure graphicRef55080 graphicRef64968 graphicRef65139 \" href=\"UTD.htm?34/36/35402\">",
"     figure 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/6\">",
"     6",
"    </a>",
"    ]. Modifications or angulations are used when standard imaging planes do not permit full depiction of the anatomy or pathology. Graphic depictions of the anatomy and normal echocardiographic dimensions from each view differ (",
"    <a class=\"graphic graphic_table graphicRef52100 \" href=\"UTD.htm?7/7/7292\">",
"     table 2",
"    </a>",
"    ). In 2005, the American Society of Echocardiography published guidelines recommending chamber quantification as part of the routine echocardiographic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRANSDUCER POSITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most echocardiography laboratories follow a fairly standard protocol for transducer orientation, beginning with parasternal views and progressing to apical, subcostal, and suprasternal positions. Almost all imaging is performed with the patient in the left lateral decubitus position during quiet respiration or extended expiration. A cutout in the mattress is helpful for maintaining optimal imaging position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Parasternal long axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the transducer in the 3rd or 4th left intercostal space, immediately adjacent to the sternum, a long-axis view of the heart is obtained which bisects the aortic and mitral valve (",
"    <a class=\"graphic graphic_figure graphicRef78316 \" href=\"UTD.htm?28/14/28896\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77446 graphicRef56587 \" href=\"UTD.htm?8/35/8757\">",
"     image 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, the \"parasternal long axis\" (PLA) view is obtained. Proper positioning of the probe results in the ascending aorta being relatively horizontal in orientation. Lower intercostal positions may be necessary in patients with vertically oriented heart. In the PLA orientation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most anterior cardiac structure is the right ventricular outflow tract. Epicardial fat, often mimicking anterior pericardial effusion, can be detected.",
"     </li>",
"     <li>",
"      The proximal structures of the ascending aorta (aortic root, sinotubular junction of the right and noncoronary sinuses), and the right (anterior) and noncoronary (posterior) leaflets of the aortic valve can be visualized. The aortic leaflets may be seen opening during ventricular systole with central coaptation (if tricuspid) point with ventricular diastole.",
"     </li>",
"     <li>",
"      The anterior and posterior mitral leaflets are also well delineated with the anterior leaflet appearing \"longer\". During early ventricular diastole, the anterior leaflet extends anteriorly, towards the interventricular septum, while the posterior leaflet moves posteriorly towards the inferolateral left ventricular wall. The leaflets then \"drift\" closed in mid-diastole, followed by a reopening during atrial systole. Ventricular systole results in leaflet closure.",
"     </li>",
"     <li>",
"      Chordae from the posterior-medial papillary muscle are commonly seen posterior to the plane of coaptation.",
"     </li>",
"     <li>",
"      Posterior to the ascending aorta, and normally equal in diameter, is the left atrium. The right pulmonary artery can be seen superior to the left atrium as it crosses under the ascending aorta. The coronary sinus, usually less than 1 cm in diameter, may be seen immediately posterior to the mitral annulus. It can be distinguished from the descending thoracic aorta as the latter is external to the pericardium.",
"     </li>",
"     <li>",
"      Posterior to the mid-left atrium, the descending thoracic aorta may be seen in cross-section (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53998 \" href=\"UTD.htm?38/4/38977\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The basal half of the anterior interventricular septum and inferoposterior wall of the left ventricle are seen, along with the muscular portion of the right ventricular outflow tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     M-mode recordings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to its very high temporal resolution of approximately 1 millisecond, M-mode can have additive information for characterizing the motion of cardiac structures. Almost all routine M-mode measurements are made from the parasternal long or short axis orientation (",
"    <a class=\"graphic graphic_figure graphicRef61898 \" href=\"UTD.htm?30/0/30725\">",
"     figure 3",
"    </a>",
"    ). To ensure proper alignment and reproducibility, all M-mode recordings are performed with 2D guidance. 2D guided M-mode measurements of the aortic leaflets and left atrium (",
"    <a class=\"graphic graphic_waveform graphicRef51366 \" href=\"UTD.htm?26/1/26645\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79751 \" href=\"UTD.htm?15/54/16228\">",
"     image 3",
"    </a>",
"    ), mitral leaflets (",
"    <a class=\"graphic graphic_waveform graphicRef74803 \" href=\"UTD.htm?37/38/38511\">",
"     waveform 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67656 \" href=\"UTD.htm?37/54/38759\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef77762 \" href=\"UTD.htm?34/1/34833\">",
"     movie 1",
"    </a>",
"    ), and left ventricle (",
"    <a class=\"graphic graphic_waveform graphicRef65151 \" href=\"UTD.htm?5/26/5539\">",
"     waveform 3",
"    </a>",
"    ) can be obtained. The tricuspid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55489 graphicRef65162 \" href=\"UTD.htm?31/42/32422\">",
"     image 4A-B",
"    </a>",
"    ) and pulmonic valves (",
"    <a class=\"graphic graphic_figure graphicRef65921 \" href=\"UTD.htm?19/8/19589\">",
"     figure 5",
"    </a>",
"    ) may also be visualized. With angulation of the transducer from the apex to the base of the heart a complete M-mode scan can be obtained (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50635 graphicRef62680 \" href=\"UTD.htm?37/17/38169\">",
"     image 5A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=see_link&amp;anchor=H12#H12\">",
"     \"Echocardiography essentials: Physics and instrumentation\", section on 'M-mode'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The M-mode echocardiogram is recorded through the coaptation point of the aortic leaflets, permitting study of the ascending aortic diameter, aortic leaflet excursion, and left atrial dimension.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ascending aorta moves anteriorly (toward the transducer) during ventricular systole. Aortic diameter is typically measured at the onset of the QRS. The coaptation of the right and noncoronary leaflets of the aortic valve appear as a single, central, thin line during ventricular diastole. In systole, the leaflets rapidly separate, resulting in a \"box-like\" profile (",
"      <a class=\"graphic graphic_waveform graphicRef51366 \" href=\"UTD.htm?26/1/26645\">",
"       waveform 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79751 \" href=\"UTD.htm?15/54/16228\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Posterior to the aorta is the left atrium. The left atrial dimension reaches is maximum at end-systole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Realignment of the M-mode beam through the anterior and posterior mitral leaflets permits visualization of mitral leaflet motion (",
"    <a class=\"graphic graphic_waveform graphicRef74803 \" href=\"UTD.htm?37/38/38511\">",
"     waveform 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67656 \" href=\"UTD.htm?37/54/38759\">",
"     figure 4",
"    </a>",
"    ). During ventricular systole, the mitral leaflets are closed with a relatively posterior closure position and slight drift anteriorly as systole progresses. During ventricular diastole and atrial systole, the anterior mitral leaflet moves towards the interventricular septum (anteriorly) while the posterior leaflet moves posteriorly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The point at the end of systole, just prior to mitral valve opening is designated as the \"D point\"",
"     </li>",
"     <li>",
"      The peak anterior deflection of the anterior leaflet is called the \"E point\"",
"     </li>",
"     <li>",
"      As left atrial and left ventricular pressure equilibrate, and intracavity flow declines, the leaflets then drift together, but rarely close unless there is bradycardia or prominent aortic regurgitation. The most posterior motion of the anterior leaflet, or its nadir, is the \"F point\" and the \"E to F slope\" is measure of early diastolic closing rate.",
"     </li>",
"     <li>",
"      This is followed by atrial systole during which the leaflets again widely separate due to atrial transport of blood across the mitral orifice into the left ventricle. The peak anterior leaflet position at this time is called the \"A point.\" This is followed by full closure of the leaflets, the \"C point.\" The posterior leaflet profile resembles the letter \"W\" and the anterior leaflet, an \"M.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moving the M-mode beam more apically, so that it is perpendicular to the left ventricle, permits measurement of end-diastolic interventricular septal thickness, inferolateral wall thickness, and left ventricular dimension throughout the cardiac cycle (",
"    <a class=\"graphic graphic_waveform graphicRef65151 \" href=\"UTD.htm?5/26/5539\">",
"     waveform 3",
"    </a>",
"    ). The left ventricular end-systolic dimension is measured at the point of maximal systolic excursions, which slightly precedes maximal inferolateral wall thickening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Right ventricular inflow and outflow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inferomedial angulation from the parasternal long-axis position is performed to obtain the 2-D \"right ventricular inflow\" view which includes the right atrium, coronary sinus, septal and anterior leaflets of the tricuspid valve and basal right ventricle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56587 \" href=\"UTD.htm?10/48/11008\">",
"     image 1B",
"    </a>",
"    ). Superior angulation of the probe permits depiction of the right ventricular outflow tract, including the pulmonic valve and main pulmonary artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Parasternal short axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the parasternal long axis orientation, a 70&ordm; to 110&ordm; clockwise rotation of the transducer with superior and inferior transducer manipulations permits delineation of the parasternal short axis views at the base (aortic valve), basal left ventricular (mitral valve), mid left ventricular (papillary muscle), and apical left ventricular levels (",
"    <a class=\"graphic graphic_figure graphicRef54326 graphicRef66915 \" href=\"UTD.htm?21/0/21513\">",
"     figure 6A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/8\">",
"     8",
"    </a>",
"    ]. At the basal (aortic valve) level, the atria and their interatrial septum, septal and anterior leaflets of the tricuspid valve, right ventricular free wall, right ventricular outflow tract, pulmonic valve, and main pulmonary artery, can be seen \"surrounding\" the centrally oriented aortic valve (",
"    <a class=\"graphic graphic_figure graphicRef67673 \" href=\"UTD.htm?12/49/13074\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63963 graphicRef64091 \" href=\"UTD.htm?19/47/20212\">",
"     image 6A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/8\">",
"     8",
"    </a>",
"    ]. All three leaflets of the aortic valve may be identified, forming a \"Y\" configuration during ventricular diastole. The origins of the left and right coronary arteries may also be identified at approximately 3 o'clock and 10 o'clock, respectively (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54573 graphicRef79123 \" href=\"UTD.htm?3/12/3268\">",
"     image 7A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The left atrial appendage can occasionally be visualized (",
"      <a class=\"graphic graphic_movie graphicRef88545 \" href=\"UTD.htm?4/11/4273\">",
"       movie 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Inferior angulation of the probe permits visualization of the left ventricle at the mitral valve level (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50331 \" href=\"UTD.htm?16/27/16816\">",
"       image 8",
"      </a>",
"      ). The left ventricle appears \"circular.\" The mitral orifice has a characteristic ovoid or \"fish-mouth\" appearance. The right ventricle is also seen.",
"     </li>",
"     <li>",
"      Slightly more inferior angulation results in visualization of the contracting left ventricle at the papillary muscle level (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82469 \" href=\"UTD.htm?18/26/18863\">",
"       image 9",
"      </a>",
"      ). In this orientation, the left ventricle may be divided into six segments: anterior, anterolateral, inferolateral, inferior, inferior septal, and anterior septal regions (",
"      <a class=\"graphic graphic_figure graphicRef55855 \" href=\"UTD.htm?1/21/1360\">",
"       figure 8",
"      </a>",
"      ). The posterior and lateral papillary muscles are well appreciated.",
"     </li>",
"     <li>",
"      Further angulation of the transducer permits visualization of more apical segments (anterior, lateral, inferior, and septal) of the left ventricle (",
"      <a class=\"graphic graphic_figure graphicRef55855 \" href=\"UTD.htm?1/21/1360\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Apical four-chamber",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the patient in left lateral recumbency, the transducer is placed on the apex (",
"    <a class=\"graphic graphic_figure graphicRef65589 \" href=\"UTD.htm?8/21/8528\">",
"     figure 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/8\">",
"     8",
"    </a>",
"    ]. In this view, all four chambers of the heart are seen simultaneously (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77637 \" href=\"UTD.htm?29/5/29791\">",
"     image 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14167/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The left ventricle appears as a truncated ellipse, with the interventricular septum, apex, and lateral walls visualized. The lateral wall of the left ventricle is displayed to the right side of the screen. Care needs to taken to avoid foreshortening the left ventricular cavity and exclusion of the true apex.",
"     </li>",
"     <li>",
"      The basal, mid, and apical free wall of the right ventricle are seen on the left side of the screen, with the moderator band connecting the free wall to the septum.",
"     </li>",
"     <li>",
"      Inferiorly positioned on the screen are the left and right atria with intervening interatrial septum. The single-plane volume of the atria may be determined from this orientation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The bottom of the image sector, the confluence of the pulmonary veins is seen superior to the left atrium. The longer anterior mitral leaflet appears medially, and posterior leaflet laterally. The closure point is normally apically displaced from the annulus. The septal and lateral tricuspid leaflets are also seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79701 graphicRef61910 \" href=\"UTD.htm?38/10/39076\">",
"     image 11A-B",
"    </a>",
"    ). The septal leaflet of the tricuspid valve is apically displaced relative to the mitral valve, and the intervening space (membranous septum) is normally less than 1.5 cm.",
"   </p>",
"   <p>",
"    Slight anterior angulation allows visualization of the anterior segment of the interventricular septum and a portion of the proximal aorta. Posterior angulation permits visualization of the coronary sinus and the posterior segment of the interventricular septum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Apical five-chamber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior angulation and slight clockwise rotation of the transducer permits imaging of the left ventricular outflow tract, right and left leaflets of the aortic valve, and proximal ascending aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54999 graphicRef65971 \" href=\"UTD.htm?41/28/42435\">",
"     image 12A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Apical two-chamber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counterclockwise rotation from the apical four-chamber orientation achieves the apical two-chamber view (",
"    <a class=\"graphic graphic_figure graphicRef56904 \" href=\"UTD.htm?42/20/43328\">",
"     figure 10",
"    </a>",
"    ). In this orientation, the anterior, inferior, and apical walls of the left ventricle are visualized, along with the left atrium and its appendage. Care should be exercised to avoid foreshortening of the left ventricle and exclusion of the apex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Apical long axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further counterclockwise rotation and anterior angulation from the apical two-chamber permits acquisition of the apical long axis view. In comparison to the apical two-chamber view, the left ventricular outflow tract, anterior septum, aortic leaflets, and proximal ascending aorta are seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77650 \" href=\"UTD.htm?17/35/17983\">",
"     image 13",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Subcostal four-chamber",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subcostal views may be obtained with the patient supine in full inspiration to bring the heart closer to the imaging probe and with the knees bent to relax the abdominal musculature. The transducer is positioned immediately below or to the right of the xiphoid process. This allows visualization of the basal, mid, and apical right ventricle, the inferior interventricular septum, and anterolateral left ventricular walls (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63231 \" href=\"UTD.htm?33/46/34528\">",
"     image 14",
"    </a>",
"    ). The interatrial septum is oriented nearly perpendicular to the ultrasound beam. Thus, interrogation for an atrial septal defect or an atrial septal aneurysm is best from this position.",
"   </p>",
"   <p>",
"    The subcostal four-chamber view is a useful orientation for measurement of right ventricular dimensions and wall thickness as well as for visualizing anterior pericardial effusions.",
"   </p>",
"   <p>",
"    Medial angulation of the transducer results in imaging of the hepatic veins and inferior vena cava as it enters the right atrium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58804 \" href=\"UTD.htm?24/55/25457\">",
"     image 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68450 \" href=\"UTD.htm?38/50/39713\">",
"     image 16",
"    </a>",
"    ). Sliding the transducer to the left allows imaging of the abdominal aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77731 \" href=\"UTD.htm?14/3/14386\">",
"     image 17",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Subcostal short axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases in which parasternal views are inadequate, rotation of the probe from the subcostal four-chamber orientation will permit acquisition of a subcostal short-axis view at the base and mid-ventricle. In this view, the inferior wall is identified by its contiguity with the liver and diaphragm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Suprasternal notch",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the patient supine and the neck extended, the transducer is placed in the suprasternal notch to obtain an image of the distal ascending, transverse, and proximal descending aorta (",
"    <a class=\"graphic graphic_figure graphicRef66074 \" href=\"UTD.htm?21/2/21536\">",
"     figure 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76850 \" href=\"UTD.htm?27/21/27985\">",
"     image 18",
"    </a>",
"    ). The take-off of the great vessels may also be appreciated. Centrally positioned and beneath the lesser curvature of the aortic arch is a short-axis view of the right pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76850 \" href=\"UTD.htm?27/21/27985\">",
"     image 18",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Right parasternal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right parasternal views may be helpful, particularly in patients with a dilated ascending aorta. With the patient in the right decubitus position, the transducer is placed in the 3rd or 4th intercostal space resulting in long axis imaging of the ascending aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Posterior orientations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusion may be seen during parasternal imaging (",
"    <a class=\"graphic graphic_movie graphicRef88546 \" href=\"UTD.htm?27/14/27873\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef59299 \" href=\"UTD.htm?1/3/1072\">",
"     figure 12",
"    </a>",
"    ). In patients with large left pleural effusion, imaging from the posterolateral or posterior thorax with the patient in the upright position may permit good quality images of cardiac structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       \"Patient information: Echocardiogram (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5894429\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transthoracic echocardiography (TTE) is the primary noninvasive imaging modality for quantitative and qualitative evaluation of cardiac anatomy and function. Two-dimensional TTE provides tomographic or \"thin slice\" imaging, with each tomographic view defined by the transducer position (parasternal, apical, subcostal, suprasternal) and view (long axis, short axis, 4 chamber, 5 chamber). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most echocardiography laboratories follow a fairly standard protocol for consecutive transducer positions, beginning with parasternal long- and short-axis views and progressing to apical four, five, two, and three chamber views, followed by subcostal, and suprasternal positions. Almost all imaging is performed with the patient in the left lateral decubitus position during quiet respiration or extended expiration. The subcostal views, however, are best obtained with the patient supine in full inspiration to bring the heart closer to the imaging probe and with the knees bent to relax the abdominal musculature. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transducer positions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14167/abstract/1\">",
"      Pearlman JD, Triulzi MO, King ME, et al. Limits of normal left ventricular dimensions in growth and development: analysis of dimensions and variance in the two-dimensional echocardiograms of 268 normal healthy subjects. J Am Coll Cardiol 1988; 12:1432.",
"     </a>",
"    </li>",
"    <li>",
"     Otto CM. Textbook of Clinical Echocardiography, 4th edition, Saunders Elsevier, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14167/abstract/3\">",
"      Wang XF, Deng YB, Nanda NC, et al. Live three-dimensional echocardiography: imaging principles and clinical application. Echocardiography 2003; 20:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14167/abstract/4\">",
"      Panza JA. Real-time three-dimensional echocardiography: an overview. Int J Cardiovasc Imaging 2001; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14167/abstract/5\">",
"      Lange A, Palka P, Burstow DJ, Godman MJ. Three-dimensional echocardiography: historical development and current applications. J Am Soc Echocardiogr 2001; 14:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14167/abstract/6\">",
"      Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14167/abstract/7\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     Parmley WW, Chatterjee K. Cardiology, Vol. 3, Lippincott, Philadelphia 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14167/abstract/9\">",
"      Silverman NH, Schiller NB. Apex echocardiography. A two-dimensional technique for evaluating congenital heart disease. Circulation 1978; 57:503.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5319 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-27C422A60D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14167=[""].join("\n");
var outline_f13_53_14167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5894429\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Orientation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tomographic views",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRANSDUCER POSITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - M-mode recordings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Right ventricular inflow and outflow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Parasternal short axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Apical four-chamber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Apical five-chamber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Apical two-chamber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Apical long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Subcostal four-chamber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Subcostal short axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Suprasternal notch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Right parasternal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Posterior orientations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5894429\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5319\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5319|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/7/20592\" title=\"diagnostic image 1A\">",
"      2D TTE parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/48/11008\" title=\"diagnostic image 1B\">",
"      2D TTE RV inflow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/4/38977\" title=\"diagnostic image 2\">",
"      2D TTE Parasternal views descending thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/54/16228\" title=\"diagnostic image 3\">",
"      2D TEE and M mode images parasternal short axis aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/54/14178\" title=\"diagnostic image 4A\">",
"      M mode tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/20/24896\" title=\"diagnostic image 4B\">",
"      2D TTE and M mode images normal tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/40/43653\" title=\"diagnostic image 5A\">",
"      M mode scan I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/11/8373\" title=\"diagnostic image 5B\">",
"      M mode scan II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/11/5296\" title=\"diagnostic image 6A\">",
"      Parasternal short axis TTE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/33/43551\" title=\"diagnostic image 6B\">",
"      2D TTE RV outflow tract view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/42/29359\" title=\"diagnostic image 7A\">",
"      2D TTE Parasternal short axis coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/50/6944\" title=\"diagnostic image 7B\">",
"      Short axis left main CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/27/16816\" title=\"diagnostic image 8\">",
"      2D TTE Parasternal short axis pap muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/26/18863\" title=\"diagnostic image 9\">",
"      2D TTE Parasternal short axis LV papillary muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/5/29791\" title=\"diagnostic image 10\">",
"      2D TTE Apical 4 chamber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/50/1824\" title=\"diagnostic image 11A\">",
"      2D TTE 2-chamber descending thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/5/18512\" title=\"diagnostic image 11B\">",
"      2D TTE 4-chamber descending thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/56/26511\" title=\"diagnostic image 12A\">",
"      2D TTE Apical 5-chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/38/5728\" title=\"diagnostic image 12B\">",
"      2D TTE Anteriorly angulated 4-chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/35/17983\" title=\"diagnostic image 13\">",
"      2D TTE Anteriorly angulated 2-chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/46/34528\" title=\"diagnostic image 14\">",
"      2D TTE Subcostal 4-chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/55/25457\" title=\"diagnostic image 15\">",
"      2D TTE Subcostal view normal IVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/50/39713\" title=\"diagnostic image 16\">",
"      M-mode subcostal view IVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/3/14386\" title=\"diagnostic image 17\">",
"      2D TTE Subcostal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/21/27985\" title=\"diagnostic image 18\">",
"      2D TTE Suprasternal view right pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5319|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/41/8850\" title=\"figure 1A\">",
"      Cardiac plane definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/55/26487\" title=\"figure 1B\">",
"      LV segmentation I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/9/16533\" title=\"figure 1C\">",
"      Coronary artery territories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/14/28896\" title=\"figure 2\">",
"      Transducer position long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/0/30725\" title=\"figure 3\">",
"      M mode echo parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/54/38759\" title=\"figure 4\">",
"      M mode mitral valve motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/8/19589\" title=\"figure 5\">",
"      M mode pulmonic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/45/42708\" title=\"figure 6A\">",
"      Transducer position for parasternal short axis view base",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/30/42468\" title=\"figure 6B\">",
"      Transducer position for parasternal short axis view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/49/13074\" title=\"figure 7\">",
"      2D TTE parasternal short axis view aortic root",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/21/1360\" title=\"figure 8\">",
"      LV wall motion analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/21/8528\" title=\"figure 9\">",
"      Transducer position apical 4 ch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/20/43328\" title=\"figure 10\">",
"      Transducer position apical 2 ch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21536\" title=\"figure 11\">",
"      2D TTE Suprasternal notch view aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/3/1072\" title=\"figure 12\">",
"      2D TTE Short axis pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5319|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?34/1/34833\" title=\"movie 1\">",
"      Normal mitral valve M mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?4/11/4273\" title=\"movie 2\">",
"      2D TTE short axis LA appendage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?27/14/27873\" title=\"movie 3\">",
"      2D TTE parasternal long axis pleural and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5319|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/12/39115\" title=\"table 1A\">",
"      Echo views cardiac structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/41/5787\" title=\"table 1B\">",
"      Echo views for valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/7/7292\" title=\"table 2\">",
"      Normal echo dimensions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5319|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/1/26645\" title=\"waveform 1\">",
"      M mode LA aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?37/38/38511\" title=\"waveform 2\">",
"      M mode mitral valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/26/5539\" title=\"waveform 3\">",
"      M mode left ventricle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=related_link\">",
"      Echocardiography essentials: Physics and instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=related_link\">",
"      Principles of Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=related_link\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_53_14168="Overview of the complications of acute myeloid leukemia";
var content_f13_53_14168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the complications of acute myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14168/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14168/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14168/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14168/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/53/14168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of acute myeloid leukemia (AML) is complex, and the care of patients with AML should be entrusted to clinicians with sufficient knowledge and experience. Symptoms associated with anemia, infection, and bleeding occur almost universally as a consequence of the treatment and the disease itself. Other complications, such as leukostasis, metabolic abnormalities, and involvement of the central nervous system (CNS) may also be life-threatening, and must be rapidly diagnosed and treated, lest they interfere with appropriate treatment of the leukemia, either before chemotherapy can be given, or during the recovery period.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the complications of AML. The clinical features, diagnosis, classification, treatment, and overall prognosis of AML are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AML typically present with a normocytic, normochromic anemia that can vary in severity. This anemia worsens with induction chemotherapy and is managed primarily with blood transfusions. There is no role for the use of erythropoietic stimulating agents during induction therapy of AML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The threshold for transfusion of packed red blood cells varies with patient age, symptoms, and the presence of medical comorbidities. In general, most centers recommend transfusion to asymptomatic patients with a hemoglobin &le;8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mmol/liter).",
"    </span>",
"    Blood products should be leukocyte depleted to reduce the risk of alloimmunization and transmission of cytomegalovirus (CMV) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although graft versus host disease is very unusual in patients with leukemia receiving conventional chemotherapy, many centers routinely irradiate blood products for such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H16#H16\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Transfusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of importance, red cell transfusions may increase the whole blood viscosity of patients with hyperleukocytosis resulting in symptoms of leukostasis. As such, red blood cell transfusions should be administered very slowly, or, if possible, withheld until the blast count is reduced in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=see_link&amp;anchor=H12#H12\">",
"     \"Hyperleukocytosis and leukostasis\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prolonged period of neutropenia associated with chemotherapy in patients with AML is frequently associated with neutropenic fevers and a high risk of infection with bacteria or fungi and viral reactivation. The prophylaxis and treatment of infectious complications in patients with AML is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H18#H18\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding in a patient with AML may be due to thrombocytopenia, other platelet disorders, or disorders of coagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Platelet disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 75 percent of patients with AML will have platelet counts below 100 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (100,000/microL)",
"    </span>",
"    at diagnosis, and about 25 percent will have counts below 25 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (25,000/microL).",
"    </span>",
"    Both morphologic and functional platelet abnormalities may be seen. Based on the results of a number of randomized trials, platelets are usually transfused prophylactically to prevent hemorrhage at counts less than",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    and at higher counts in patients with active bleeding or with clinical problems such as hyperleukostasis, fever, severe infection, pulmonary compromise, or coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558395349#H558395349\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Leukemia and chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is a common complication of malignancy, and can be a prominent feature in patients with acute promyelocytic leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DIC can be seen with all leukemia subtypes. It is often present in association with hyperleukocytosis in patients with acute myelomonocytic or acute monocytic leukemia. Coagulation profiles including fibrinogen and measurements of fibrin degradation products should be obtained at the time of leukemia diagnosis.",
"   </p>",
"   <p>",
"    Treatment with platelet transfusions and appropriate coagulation factors (eg, cryoprecipitate for severe hypofibrinogenemia) can be considered in select situations. It should be noted that the plasma in which platelets are suspended contains coagulation factors that can be of sufficient concentration for patients with milder DIC. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Control of coagulopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Menorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women are at risk for severe and prolonged menorrhagia during induction therapy. Prevention and treatment of this complication is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=see_link\">",
"     \"Heavy or irregular uterine bleeding during chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPERLEUKOCYTOSIS AND LEUKOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperleukocytosis has been variably defined in the setting of AML as a total white blood cell count greater than 50 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (50,000/microL)",
"    </span>",
"    or greater than 100 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (100,000/microL).",
"    </span>",
"    It is present in 10 to 20 percent of patients with newly diagnosed AML. Symptomatic hyperleukocytosis (ie, leukostasis), typically presenting with respiratory or neurological distress, constitutes a",
"    <strong>",
"     medical emergency",
"    </strong>",
"    . An absolute myeloblast count approaching",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    is a medical emergency even in the asymptomatic patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=see_link\">",
"     \"Hyperleukocytosis and leukostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     METABOLIC ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AML can experience a wide range of metabolic problems as a consequence of vomiting, diarrhea, impaired nutrition, excessive fluid administration, diuretics, or renal dysfunction, usually due to side effects from the use of antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy.",
"   </p>",
"   <p>",
"    Other metabolic disorders are related to the leukemic process itself, and are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tumor lysis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor lysis syndrome, caused by rapid leukemic cell death following the onset of chemotherapy, can be seen in patients with AML, especially those with hyperleukocytosis, impaired baseline renal function, and hyperuricemia at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor lysis syndrome is characterized by hyperphosphatemia, hypocalcemia, hyperuricemia, hyperkalemia, and renal insufficiency. The inciting cause seems to be release of large amounts of phosphate from lysed blasts, which coprecipitates with calcium in the kidneys, leading to hypocalcemia and sometimes to oliguric renal failure. Hyperuricemia further contributes to this problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricemia is the most frequent metabolic abnormality seen in patients with AML. It is also one of the diagnostic criteria for tumor lysis syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperuricemia can result in renal insufficiency due to uric acid nephropathy, as well as acute gout. Patients should receive intravenous hydration and medical therapy to reduce uric acid levels during induction therapy. The prevention and treatment of tumor lysis syndrome is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperphosphatemia is seen in patients with AML and tumor lysis syndrome. Acute severe hyperphosphatemia with symptomatic hypocalcemia can be life-threatening. Treatment includes vigorous hydration, if possible, and the administration of a phosphate binder with or without dialysis (",
"    <a class=\"graphic graphic_table graphicRef70281 \" href=\"UTD.htm?4/30/4590\">",
"     table 1",
"    </a>",
"    ). The prevention and treatment of tumor lysis syndrome is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=see_link\">",
"     \"Overview of the causes and treatment of hyperphosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia is a component of tumor lysis syndrome. Patients with acute hypocalcemia and hyperphosphatemia due to tumor lysis syndrome should NOT be treated with calcium until the hyperphosphatemia is corrected. Hemodialysis is often indicated in such patients who have renal failure (",
"    <a class=\"graphic graphic_table graphicRef70281 \" href=\"UTD.htm?4/30/4590\">",
"     table 1",
"    </a>",
"    ). The prevention and treatment of tumor lysis syndrome is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia can occur as a consequence of renal dysfunction in patients with severe tumor lysis syndrome. Treatments include insulin plus glucose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , beta-2-adrenergic agonists, loop or thiazide diuretics, cation exchange resin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dialysis (",
"    <a class=\"graphic graphic_table graphicRef70281 \" href=\"UTD.htm?4/30/4590\">",
"     table 1",
"    </a>",
"    ). The prevention and treatment of tumor lysis syndrome is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperkalemia can also be an artifact of blood drawing in patients with AML, a phenomenon called pseudohyperkalemia. In this setting, the plasma potassium is normal but the measured serum potassium may be elevated due to release of potassium from the increased number of white cells during clotting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Pseudohyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H896838\">",
"    <span class=\"h2\">",
"     Hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe, occasionally symptomatic, hypokalemia is not infrequent, particularly in patients with monocytic leukemias. The mechanism appears to be renal potassium loss secondary to tubular damage induced by high levels of lysozyme [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/7\">",
"     7",
"    </a>",
"    ]. Aggressive replacement with parenteral potassium is required; hypokalemia usually abates after cytoreduction by chemotherapy. Another mechanism of hypokalemia is a side effect of therapy with certain drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H16897924#H16897924\">",
"     \"Causes of hypokalemia\", section on 'Salt-wasting nephropathies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H21#H21\">",
"     \"Causes of hypokalemia\", section on 'Amphotericin B'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3820210#H3820210\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Severe or symptomatic hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypokalemia can also represent an artifact of blood drawing in patients with AML and a high white blood cell count. In this setting, the plasma potassium concentration is normal but, if the blood is allowed to stand at room temperature, extracellular potassium may be taken up by the metabolically active leukemic cells, resulting in a fall in the measured potassium concentration to as low as 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/8\">",
"     8",
"    </a>",
"    ]. This phenomenon has been called pseudohypokalemia or spurious hypokalemia. It can be prevented by either rapid separation of plasma from the cells following venipuncture or storage of the blood at 4&deg;C before assay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of hypokalemia\", section on 'Increased blood cell production'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early in the clinical course, hypokalemia may be aggravated by the uptake of potassium by the leukemic cells, while later in the course it may be aggravated by the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of hypokalemia\", section on 'Increased blood cell production'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H21#H21\">",
"     \"Causes of hypokalemia\", section on 'Amphotericin B'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite markedly hypercellular marrows, hypercalcemia is extremely unusual in AML [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/4\">",
"     4",
"    </a>",
"    ]. It has been described in other leukemic conditions, such as plasma cell leukemia, blast crisis in chronic myeloid leukemia, and adult T-cell leukemia-lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16039?source=see_link\">",
"     \"Plasma cell leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"     \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lactic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare patients have been described in whom lactic acidosis has been a metabolic accompaniment of the leukemia, both at the time of presentation and relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ]. The mechanism is unclear, although anaerobic metabolism by the leukemic cells at sites of leukostasis has been postulated. The prognosis of this complication is grave; chemotherapy, if effective, corrects the acute acidosis in some, but not all, patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CNS LEUKEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the central nervous system (CNS) at the time of AML diagnosis is uncommon and routine evaluation is not recommended for asymptomatic patients. Likewise, clinically overt CNS involvement developing at some point during the course of treatment is uncommon, perhaps related to the administration of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    as post-remission therapy. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OCULAR INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any ocular structure may be involved in acute leukemia and ocular involvement more frequently dominated the clinical picture in the prechemotherapy era [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/11\">",
"     11",
"    </a>",
"    ]. Involvement of the choroid and retina is most common. However, leukemic cells can infiltrate the conjunctiva and lacrimal glands, producing obvious masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ophthalmic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having ocular involvement should undergo a full evaluation by an ophthalmologist including a slit lamp examination [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A comprehensive, prospective study of 53 newly diagnosed adults with AML documented retinal or optic nerve abnormalities in 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/14\">",
"     14",
"    </a>",
"    ]. Hemorrhage and cotton wool spots (a consequence of nerve fiber ischemia) were the most frequent findings. Their occurrence was unrelated to patient age, AML subtype, white blood cell count, or hematocrit. Initial platelet counts were lower in patients with retinopathy. Ten patients had decreased visual acuity, including five with macular hemorrhages. Cotton wool spots may be a consequence of or exacerbated by ischemia due to anemia. Definite leukemic infiltration of the retina could not be confirmed in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ocular involvement, but no other evidence of CNS involvement, are treated in a similar fashion to patients without CNS involvement (ie, induction chemotherapy followed by post-remission therapy). Early empiric use of antifungal therapy has decreased the likelihood of hematogenous spread of fungal infection to the eye.",
"   </p>",
"   <p>",
"    All patients in the study described above received induction chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/14\">",
"     14",
"    </a>",
"    ]; no patient received intrathecal chemotherapy or cranial or ocular irradiation. All ocular findings resolved in patients achieving complete remission and there was no residual visual deficit in any patient. Infectious ocular problems were not noted and seem to be uncommon, perhaps because of the rapid, empiric use of antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NEUTROPENIC ENTEROCOLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenic enterocolitis (neutropenic enterocolitis, typhlitis) tends to occur after chemotherapy administration at the time of the neutrophil count nadir, and has been associated with high mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutropenic enterocolitis must be considered in the differential diagnosis of any profoundly neutropenic patient (absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &lt;500/microL)",
"    </span>",
"    who presents with abdominal pain, usually in the right lower quadrant, with or without fever. Additional symptoms may include abdominal distension, nausea, vomiting, and watery or bloody diarrhea. Peritoneal signs and shock suggest the possibility of bowel wall perforation. It is usually diagnosed by characteristic findings on computed tomography scan in high-risk patients. Early imaging should be encouraged whenever the suspicion of this potentially lethal entity arises. Tests to exclude infection with clostridium difficile should be done, particularly in patients with significant diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H15443523#H15443523\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management is mostly supportive, although surgical intervention may be required if bowel wall perforation, necrosis, or uncontrollable bleeding is present. Use of myeloid colony stimulating factors and granulocyte transfusions may be considered in select patients with an expected prolonged duration of neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27125?source=see_link\">",
"     \"Typhlitis (neutropenic enterocolitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link&amp;anchor=H41#H41\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on 'Neutropenic enterocolitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=see_link\">",
"     \"Granulocyte transfusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     JOINT INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasion of the synovial membrane of the joints with leukemic blasts is an uncommon manifestation of AML. It may antedate the clinical diagnosis of AML, may mimic other acute arthritic syndromes such as rheumatoid arthritis, and responds only to treatment directed at the leukemic process [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link&amp;anchor=H19#H19\">",
"     \"Malignancy and rheumatic disorders\", section on 'Leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AML may have an increased risk of developing venous thromboembolism (VTE), especially during the first three months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/19\">",
"     19",
"    </a>",
"    ]. Retrospective analyses have reported incidence rates of VTE among patients with AML that range from 2 to 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. The incidence appears to be higher in patients with acute promyelocytic leukemia with rates of 6 to 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. The majority of thromboses appear to occur within the first month of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/24\">",
"     24",
"    </a>",
"    ]. Most of the thromboses that have been described are related to the presence of indwelling catheters.",
"   </p>",
"   <p>",
"    No controlled studies or society guidelines are available to guide decisions regarding prophylaxis or treatment of VTE in patients with AML. Prophylaxis for VTE is not commonly given to patients with AML because of the prolonged thrombocytopenia and associated bleeding risk during induction treatment. However, severe thrombocytopenia does not completely eliminate the risk of VTE in this population. VTE may be related to prolonged immobility and venous stasis from bed rest during induction therapy. Therefore, it is reasonable to encourage patients to be out of bed as much as possible during the induction phase of therapy. In addition, increased early mobility may also help ameliorate leg edema that frequently complicates induction therapy.",
"   </p>",
"   <p>",
"    The treatment of VTE in patients with malignancy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=see_link\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ACUTE PULMONARY FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pulmonary failure (APF) during induction therapy for AML is an uncommon but serious complication. Potential causes include lung hemorrhage, capillary leak from tumor lysis or fluid overload, infections, sepsis, and the differentiation syndrome in patients with acute promyelocytic leukemia treated with ATRA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link&amp;anchor=H12#H12\">",
"     \"Differentiation (retinoic acid) syndrome\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link&amp;anchor=H21#H21\">",
"     \"Differentiation (retinoic acid) syndrome\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of 1541 patients referred for remission induction chemotherapy for AML or high-risk myelodysplasia, 120 (8 percent) developed APF and required ventilatory support within two weeks of the initiation of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/25\">",
"     25",
"    </a>",
"    ]. The mortality rate during induction therapy for these patients was 73 percent.",
"   </p>",
"   <p>",
"    Multivariable analysis indicated five prognostic features predicting for APF: male sex, FAB M3 morphology, poor performance status, lung infiltrates at diagnosis, and increased serum creatinine. Patients with zero to 1, 2, 3, or 4 to 5 adverse factors had estimated incidences of APF of 3, 13, 23, and 34 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PERICARDIAL EFFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data describing the incidence and complications of pericardial effusions in patients with AML. In a retrospective study of 2592 patients with acute leukemia or myelodysplastic syndrome, echocardiogram data was available for 1600 patients (62 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14168/abstract/26\">",
"     26",
"    </a>",
"    ]. A pericardial effusion was present in 21 percent of patients with AML, 70 percent of which were minimal or trace in size. Moderate or large effusions accounted for only 5 and 0.5 percent, respectively, and only 3 percent of effusions required pericardiocentesis due to tamponade at the time of detection. Patients with pericardial effusions had similar survival rates to those without effusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link\">",
"     \"Pericardial disease associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute myeloid leukemia (AML) frequently encounter complications, either due to their underlying disease or related to the administration of chemotherapy. These complications must be diagnosed quickly so that appropriate interventions can be taken.",
"   </p>",
"   <p>",
"    The most common complications are anemia, infection, and bleeding. Other complications, such as leukostasis, metabolic abnormalities, involvement of the central nervous system, and neutropenic enterocolitis may also be life-threatening, and must be rapidly diagnosed and treated, lest they compromise the outcome of chemotherapy.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/1\">",
"      Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/2\">",
"      Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/3\">",
"      Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/4\">",
"      Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/5\">",
"      Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 1981; 60:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/6\">",
"      Chumbley LC. Pseudohyperkalemia in acute myelocytic leukemia. JAMA 1970; 211:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/7\">",
"      Wiernik PH, Serpick AA. Clinical significance of serum and urinary muramidase activity in leukemia and other hematologic malignancies. Am J Med 1969; 46:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/8\">",
"      Adams PC, Woodhouse KW, Adela M, Parnham A. Exaggerated hypokalaemia in acute myeloid leukaemia. Br Med J (Clin Res Ed) 1981; 282:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/9\">",
"      Sillos EM, Shenep JL, Burghen GA, et al. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer 2001; 92:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/10\">",
"      Spinazz&eacute; S, Schrijvers D. Metabolic emergencies. Crit Rev Oncol Hematol 2006; 58:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/11\">",
"      Rosenthal AR. Ocular manifestations of leukemia. A review. Ophthalmology 1983; 90:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/12\">",
"      Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/13\">",
"      Sharma T, Grewal J, Gupta S, Murray PI. Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role. Eye (Lond) 2004; 18:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/14\">",
"      Karesh JW, Goldman EJ, Reck K, et al. A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings. J Clin Oncol 1989; 7:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/15\">",
"      Schnoll-Sussman F, Kurtz RC. Gastrointestinal emergencies in the critically ill cancer patient. Semin Oncol 2000; 27:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/16\">",
"      Luzar MJ, Sharma HM. Leukemia and arthritis: including reports on light, immunofluorescent, and electron microscopy of the synovium. J Rheumatol 1983; 10:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/17\">",
"      Marsh WL Jr, Bylund DJ, Heath VC, Anderson MJ. Osteoarticular and pulmonary manifestations of acute leukemia. Case report and review of the literature. Cancer 1986; 57:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/18\">",
"      Evans TI, Nercessian BM, Sanders KM. Leukemic arthritis. Semin Arthritis Rheum 1994; 24:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/19\">",
"      Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27:4848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/20\">",
"      Ku GH, White RH, Chew HK, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113:3911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/21\">",
"      Ziegler S, Sperr WR, Kn&ouml;bl P, et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005; 115:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/22\">",
"      Mohren M, Markmann I, Jentsch-Ullrich K, et al. Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer 2006; 94:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/23\">",
"      De Stefano V, Sor&agrave; F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/24\">",
"      Melillo L, Grandone E, Colaizzo D, et al. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 2007; 117:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/25\">",
"      Al Ameri A, Koller C, Kantarjian H, et al. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2010; 116:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14168/abstract/26\">",
"      Sampat K, Rossi A, Garcia-Gutierrez V, et al. Characteristics of pericardial effusions in patients with leukemia. Cancer 2010; 116:2366.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4510 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14168=[""].join("\n");
var outline_f13_53_14168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Platelet disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPERLEUKOCYTOSIS AND LEUKOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      METABOLIC ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tumor lysis syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H896838\">",
"      Hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CNS LEUKEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OCULAR INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ophthalmic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NEUTROPENIC ENTEROCOLITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      JOINT INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ACUTE PULMONARY FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PERICARDIAL EFFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4510\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4510|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/30/4590\" title=\"table 1\">",
"      Mgmt electrolyte abn TLS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=related_link\">",
"      Differentiation (retinoic acid) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=related_link\">",
"      Granulocyte transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=related_link\">",
"      Heavy or irregular uterine bleeding during chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=related_link\">",
"      Involvement of the central nervous system with acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=related_link\">",
"      Overview of the causes and treatment of hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16039?source=related_link\">",
"      Plasma cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=related_link\">",
"      Treatment and prognosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=related_link\">",
"      Treatment of venous thromboembolism in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27125?source=related_link\">",
"      Typhlitis (neutropenic enterocolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_53_14169="Pathogenesis and biology of malignant gliomas";
var content_f13_53_14169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and biology of malignant gliomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14169/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14169/contributors\">",
"     David N Louis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14169/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14169/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14169/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14169/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/53/14169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gliomas are primary brain tumors that display histological features of glial cells (ie, astrocytes, oligodendrocytes, and ependymal cells). The diffuse gliomas are the most common types and generally affect the cerebral hemispheres of adults. They are classified based upon their line of differentiation and are graded according to their histological degree of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link\">",
"     \"Classification of gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathology and biology of these malignant gliomas are reviewed here. The clinical manifestations, diagnosis, and treatment of these tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"     \"Adjuvant radiation therapy for malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"     \"Adjuvant chemotherapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 World Health Organization (WHO) scheme is the most widely accepted approach to the classification of these tumors (",
"    <a class=\"graphic graphic_table graphicRef55058 \" href=\"UTD.htm?14/32/14861\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ]. Malignant (high-grade) gliomas are classified and graded as either grade III anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma, or as grade IV glioblastoma (glioblastoma, GBM). A new, provisional category of tumors is glioblastoma with an oligodendroglioma component, which is WHO grade IV. At least 80 percent of malignant gliomas are GBMs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the term \"diffuse glioma\" suggests, these are all diffusely infiltrative tumors that display invasion into the cerebral parenchyma. These tumors typically involve the white matter of the cerebral hemispheres, but may occur primarily in gray matter as well as in other regions of the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/2\">",
"     2",
"    </a>",
"    ]. Their highly infiltrative nature often prevents curative surgical resections and complicates effective delivery of many kinds of therapy.",
"   </p>",
"   <p>",
"    As the tumors increase in histologic grade, additional features of malignancy are noted. In general, mitotic activity characterizes anaplastic, grade III tumors (",
"    <a class=\"graphic graphic_picture graphicRef73766 \" href=\"UTD.htm?16/11/16566\">",
"     picture 1",
"    </a>",
"    ), while microvascular proliferation and necrosis define grade IV lesions (",
"    <a class=\"graphic graphic_picture graphicRef50499 \" href=\"UTD.htm?25/24/25990\">",
"     picture 2",
"    </a>",
"    ). However, specific neuropathologic grading criteria vary between astrocytomas and oligodendroglial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Astrocytic tumors, including the highly malignant GBM, are composed of cells with elongated or irregular, hyperchromatic nuclei and eosinophilic, glial fibrillary acidic protein (GFAP)-positive cytoplasm. In contrast, oligodendrogliomas have rounded nuclei, often with perinuclear halos, calcification and delicate, branching blood vessels. Oligoastrocytomas have histologic features of both astrocytic and oligodendroglial gliomas. All of these tumors can have significant regional heterogeneity, and the tumors are graded histologically according to their most anaplastic appearing areas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gliosarcomas are a subset of GBMs and comprise approximately 2 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/4\">",
"     4",
"    </a>",
"    ]. At a light microscope level, these tumors appear to contain two neoplastic cell populations, one glial and the other mesenchymal, but molecular data suggest that these are clonal glial tumors. The biologic behavior of gliosarcomas appears to be similar to that of other GBMs.",
"   </p>",
"   <p>",
"    Some malignant gliomas arise from grade II diffuse gliomas (eg, a GBM may occur in the setting of a prior grade II astrocytoma). These tumors, which are more common in younger patients, have been termed \"secondary\". Other malignant gliomas apparently arise de novo, without a history of a prior lower-grade lesion; these have been termed \"primary\" and are more common in older patients. The spectrum of genetic abnormalities differs between primary and secondary glioblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular genetics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our understanding of the molecular genetic basis of malignant gliomas has increased markedly over the last two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This knowledge has provided insight into the biological basis of malignant glioma formation and progression. Importantly, this information has permitted the generation of novel genetically engineered murine models of diffuse malignant glioma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Some of these molecular changes may represent potential targets for future gene or molecular pharmacological therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link\">",
"     \"Experimental treatment approaches for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The basic molecular genetic and biological changes that are associated with gliomas are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703112\">",
"    <span class=\"h2\">",
"     Cell of origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current studies suggest that malignant gliomas arise from neural progenitor cells but the precise stage of differentiation of such target cells (ie, stem cells versus progenitor cells) is not clear. Malignant gliomas contain multipotent tumor stem cells that are responsible for populating and repopulating the tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. These tumor stem cells may be transformed variants of normal neural progenitor cells. The existence of these tumor stem cells may have therapeutic implications, since therapies that do not ablate the tumor stem cells will be ineffective in eradicating the tumor. Nonetheless, the cell or origin of malignant gliomas remains controversial, and the possibility that these tumors arise from a fully differentiated cell type, such as a mature glial cell, has not been formally excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Molecular genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other human cancers, the formation and progression of diffuse gliomas is accompanied by activation of oncogenes, inactivation of tumor suppressor genes, abrogation of apoptotic genes and deregulation of DNA repair genes. Different constellations of genetic alterations are associated with specific types of malignant gliomas, with particular tumor grades, and with differential sensitivities to specific therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Formation of astrocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of WHO grade II astrocytoma is associated with at least three moderately common genetic alterations: inactivation of the TP53 tumor suppressor gene, heterozygous point mutations of the isocitrate dehydrogenase-1 (IDH1) or less commonly IDH2, and loss of chromosome 22q [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the specific gene on chromosome 22q remains to be identified, the TP53 and IDH genes have been extensively studied in gliomas.",
"   </p>",
"   <p>",
"    TP53 maps to chromosome 17p and it encodes the p53 protein, which has an integral role in a number of cellular processes, including cell cycle arrest, response to DNA damage, and apoptosis (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular biology'",
"    </a>",
"    below). Inactivation of the TP53 gene, usually due to mutation of one copy and chromosomal loss of the remaining allele, occurs in about one-half of astrocytomas and about one-third of anaplastic astrocytomas and glioblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. The TP53 mutations are primarily missense mutations and target the evolutionarily-conserved domains in exons 5, 7 and 8. Particular mutational hot spots include codons 175, 248 and 273, in which C to T transitions are most likely the result of spontaneous deamination of 5-methylcytosine residues. These mutations affect p53 residues that are crucial for DNA binding, presumably leading to loss of p53-mediated function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatic mutations at codon 132 in IDH1 are present in 50 to 80 percent of WHO grade II and III astrocytic tumors and oligodendroglial tumors, as well as in secondary grade IV glioblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, these IDH1 mutations are only found in about 5 percent of primary glioblastomas. IDH1 mutations are rare in other central nervous system tumors.",
"   </p>",
"   <p>",
"    Mutations in IDH2 (codon 172) are detectable in the same spectrum of WHO grade II and III astrocytic and glial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/13\">",
"     13",
"    </a>",
"    ]. However, IDH2 mutations are present in only about 5 percent of these tumors.",
"   </p>",
"   <p>",
"    Several large studies have observed that the presence of a characteristic mutation in IDH1 or IDH2 has prognostic implications, with a significantly prolonged progression-free survival and overall survival compared with comparable tumors without an IDH mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of mutations in IDH appears to be useful for distinguishing diffuse astrocytoma from reactive astrocytosis (gliosis) particularly in biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/18\">",
"     18",
"    </a>",
"    ]. The importance of this finding was initially demonstrated based upon mutation analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/19\">",
"     19",
"    </a>",
"    ]; more recently, immunohistochemistry to detect the mutant IHD1 protein has been shown to be specific for astrocytoma rather than astrocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of putative mechanisms have been suggested for IDH dysregulation in glioma formation. IDH1 mutants may act as dominant negative inhibitors of wild-type IDH1 function, exerting a tumorigenic effect through induction of the HIF-1 alpha pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/20\">",
"     20",
"    </a>",
"    ]. Another possibility is that heterozygous IDH1 mutants foster the formation of an oncogenic metabolite, R(-)-2-hydroxyglutarate (2HG) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/21\">",
"     21",
"    </a>",
"    ]. In leukemias, IDH mutation and 2HG production has been linked via DNA methylation changes to impaired hematopoietic cell differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/22\">",
"     22",
"    </a>",
"    ], and it remains possible that related effects occur in glial cells. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Transition to malignant glioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transition from low grade to anaplastic astrocytoma is associated with inactivation of tumor suppressor genes on chromosomes 9p, 13q and 19q (",
"    <a class=\"graphic graphic_figure graphicRef74978 \" href=\"UTD.htm?2/25/2463\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Loss of chromosome 13q, which includes the retinoblastoma (RB) gene locus, occurs in approximately one-third of higher-grade astrocytic tumors (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular biology'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately two-thirds of malignant astrocytomas and glioblastomas have homozygous deletions of the region of chromosome 9p that includes the CDKN2A and CDKN2B genes (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular biology'",
"    </a>",
"    below). In general, alterations of RB, CDKN2A and the CDK4 gene are mutually exclusive in glioblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malignant progression to glioblastoma is also associated with inactivation of the PTEN tumor suppressor gene on chromosome 10 and amplification of the EGFR gene (",
"    <a class=\"graphic graphic_figure graphicRef74978 \" href=\"UTD.htm?2/25/2463\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/24\">",
"     24",
"    </a>",
"    ]. Chromosome 10 loss occurs in 60 to 85 percent of glioblastomas, with approximately 25 percent of cases having PTEN mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/25\">",
"     25",
"    </a>",
"    ]. The EGFR gene is amplified in approximately 40 percent of all glioblastomas (less commonly in anaplastic astrocytomas), resulting in overexpression of EGFR, a transmembrane receptor tyrosine kinase (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular biology'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/12\">",
"     12",
"    </a>",
"    ]. Approximately one-third of glioblastomas with EGFR gene amplification also have gene rearrangements, some encoding truncated, constitutively active mutants; by far the most common of these is known as variant III (vIII) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Genetic subsets of glioblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;EGFR gene amplification-associated glioblastomas may arise de novo or rapidly from a preexisting tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. In contrast, EGFR gene amplification almost never occurs in glioblastomas with TP53 mutation or loss of chromosome 17p [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, approximately one-third of glioblastomas have TP53 inactivation, one-third have EGFR gene amplification, and one-third have neither of these changes.",
"   </p>",
"   <p>",
"    The glioma pathway that includes TP53 inactivation most often involves progression from a lower-grade astrocytoma, the so-called \"secondary glioblastoma\" (",
"    <a class=\"graphic graphic_figure graphicRef74978 \" href=\"UTD.htm?2/25/2463\">",
"     figure 1",
"    </a>",
"    ). These glioblastomas tend to occur in significantly younger adults than glioblastomas with EGFR gene amplification. On the other hand, glioblastomas with EGFR amplification typically occur in older patients who do not have a history of preceding lower-grade astrocytoma, so-called \"primary glioblastoma.\"",
"   </p>",
"   <p>",
"    Parallel progression scenarios have been suggested for IDH mutation, with the majority of grade II and III astrocytomas and &ldquo;secondary glioblastomas&rdquo; associated with IDH mutations and better prognosis, and the majority of &ldquo;primary glioblastomas&rdquo; associated with absence of IDH mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Formation of astrocytoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Integrated analyses of gene expression profiles from large databases suggest that glioblastomas can be divided into proneural, neural, classical, and mesenchymal subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/26\">",
"     26",
"    </a>",
"    ]. To date, however, studies of genetic subsets of glioblastoma have revealed a few associations, but no clear correlations of genotype with tumor behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/27\">",
"     27",
"    </a>",
"    ]. Nonetheless, the ability of molecular genetics to assess biological heterogeneity in glioblastomas raises the possibility that new approaches to diagnosis and treatment will be based on objective biological parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CpG island methylator phenotype may also provide another means to subdivide glioblastomas. Analysis of tissue from a GBM tumor tissue database identified a subset of tumors that were characterized by promoter hypermethylation at a large number of loci [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/28\">",
"     28",
"    </a>",
"    ]. Tumors containing this promoter hypermethylation were more commonly low-grade and were observed in younger patients. These tumors were associated with IDH1 mutations and a better prognosis compared to those without the hypermethylation phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Formation of oligodendroglioma and oligoastrocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncogene amplification has only rarely been noted in oligodendroglial tumors. Chromosomal losses in oligodendrogliomas and oligoastrocytomas preferentially affect chromosomes 1p and 19q, occurring in 40 to 80 percent of these tumor types [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ]. These two events are typically found together in oligodendrogliomas, presumably on the basis of a single translocation event [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the frequent loss of these loci in low-grade as well as anaplastic oligodendrogliomas and oligoastrocytomas,",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    loss is probably important early in oligodendroglial tumorigenesis. Those oligoastrocytomas that do not harbor 1p and 19q loss will sometimes have genetic changes more characteristic of astrocytomas, suggesting that molecular genetic analysis may play a role in distinguishing more oligodendroglial from more astrocytic oligoastrocytomas. Anaplastic oligodendrogliomas and anaplastic oligoastrocytomas additionally display allelic losses of chromosomes 9p and 10, loci which are, as discussed above, integral to glioma progression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of the CIC gene on chromosome 19q13.2 have recently been found in oligodendrogliomas, particularly in those with IDH mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], but the functional significance of mutations in this gene remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Genetic subsets of anaplastic oligodendroglioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the common malignant gliomas, anaplastic oligodendrogliomas are distinguished by their chemosensitivity, both to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    or the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    (CCNU) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (PCV). While no clinical or pathological feature predicts chemotherapeutic response accurately, allelic loss of chromosome 1p and 19q is a powerful predictor of chemotherapeutic response and longer recurrence-free survival following chemotherapy in patients with anaplastic oligodendrogliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Recently, it has been shown that those anaplastic oligodendrogliomas that have both",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    loss and polysomies of chromosomes 1 and 19 have intermediate prognoses, with shorter progression-free survivals than those tumors with only",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    loss [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features, pathology, and prognostic factors for oligodendroglial tumors\", section on 'Codeletion 1p/19q'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H21\">",
"     'Chemotherapy responsiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Such data imply that differential clinical behaviors reflect two independent genetic subtypes of anaplastic oligodendroglioma. The results further suggest that molecular genetic analyses may eventually guide therapeutic decision in patients with particular types of malignant glioma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Molecular biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above genetic alterations are cardinal events in the formation and progression of these diffuse malignant gliomas. Some of the specific genetic alterations are likely related to particular tumorigenic events [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/6,38\">",
"     6,38",
"    </a>",
"    ]. These are overviewed below, but it should be emphasized that such events do not take place in isolation and that it is the combined effect of multiple tumorigenic converging on key regulatory pathways that cause human cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Growth factor overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of growth factors, or oncogenes, are overexpressed in malignant gliomas and thus provide a growth advantage to neoplastic cells. In general, glioma cells express both the ligand growth factor and its receptor, setting up an autocrine growth-promoting loop. Some growth factors are highly expressed in low-grade as well as malignant gliomas, whereas others are primarily overexpressed only in glioblastomas. A list of the growth factors or their respective receptors involved in malignant gliomas includes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet-derived growth factor (PDGF)",
"     </li>",
"     <li>",
"      Epidermal growth factor receptor (EGFR)",
"     </li>",
"     <li>",
"      Basic fibroblast growth factor (bFGF, FGF-2)",
"     </li>",
"     <li>",
"      Transforming growth factor (TGF)-alpha",
"     </li>",
"     <li>",
"      Insulin-like growth factor (IGF)-1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, PDGF and EGFR have been most studied. The A chain of the PDGF ligand is expressed in the vast majority of diffuse astrocytic tumors, along with its cognate alpha receptor and is therefore viewed as an early change in astrocytoma tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/39\">",
"     39",
"    </a>",
"    ]. Other growth factors like EGFR, however, are primarily upregulated only in glioblastomas, suggesting that these molecules are involved in progression rather than initiation of gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ]. The mechanisms for such growth factor overexpression also vary between growth factors. For example, as noted above, EGFR overexpression arises as a result of gene amplification, whereas PDGF and PDGF receptor overexpression occurs at the transcriptional level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Loss of cell cycle control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progression of the normal cell cycle is under intricate control. Clearly, however, glioma cells develop means for eliminating such control, giving them a growth advantage. As expected, many of the genetic defects in growth regulatory molecules occur preferentially in malignant, rather than low grade, gliomas. In fact, the transition from the more slowly growing grade II gliomas to the aggressive, anaplastic, grade III lesions is attended by cell cycle deregulation; hence, the histological appearance of mitotic activity in grade III gliomas. The cell cycle checkpoint that has received the most attention has been the G1-S phase transition.",
"   </p>",
"   <p>",
"    One of the major pathways controlling this checkpoint involves the p16, cyclin dependent kinase (CDK)-4, cyclin D, and pRB (retinoblastoma) proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ]. As noted above (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular genetics'",
"    </a>",
"    above), alterations of at least one component of this pathway occur in many anaplastic astrocytomas and in the vast majority of glioblastomas. The protein encoded by the RB gene, pRB, is important in cell-cycle arrest; the loss of pRB function in gliomas thereby removes an important brake on the cell cycle.",
"   </p>",
"   <p>",
"    One upstream mediator of pRB function is the p16 product of the CDKN2A gene (also called p16INK4A) on chromosome 9p, a tumor suppressor inactivated in a number of human tumors. p16 inhibits the cyclin-cyclin dependent kinase complex that regulates RB. The vast majority of glioma cell lines and two-thirds of malignant gliomas show homozygous deletions of chromosome 9p that include this gene. It is likely that these deletions result in loss of expression of the p16 and p14ARF transcripts from CDKN2A and the p15 transcript from the nearby CDKN2B (also called MTS2 [multiple tumor suppressor 2]), resulting in loss of multiple cell cycle control checkpoints and greater proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the CDK4 (cyclin dependent kinase 4) gene is amplified and overexpressed in 10 to 15 percent of malignant gliomas. CDK4 itself is regulated by p16 and inactivates pRB through phosphorylation. Thus, nearly all high-grade tumors have impairments of this single critical cell cycle control pathway. It is likely as well that less profound defects in cell cycle regulation occur in lower-grade gliomas; for instance, TP53 gene mutations may affect both the G1-S and G2-M checkpoints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Dysregulation of apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most normal cells activate cell death (apoptotic) pathways in response to DNA damage or abnormal proliferation. Thus, tumor cells must develop means not only for increasing proliferation but for abrogating apoptosis as well. A number of genes implicated in malignant glioma pathogenesis have roles in apoptosis pathways, most notably TP53. TP53 mutations may impede the normal glial apoptotic response that would follow growth factor overexpression in low-grade gliomas, allowing further tumorigenesis to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Genomic instability and malignant progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cardinal feature of diffuse low-grade gliomas is their nearly universal progression to higher grade lesions over time. Such malignant progression is related to the emergence of more malignant clones. The presence of genomic instability, a feature of many tumors, encourages further genomic damage, thus allowing the eventual selection of more malignant clones. TP53 has been dubbed \"the guardian of the genome\" because of its role in protecting cells from DNA damage. Mutations of TP53 may therefore lead to tumor progression through genomic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ]. Interestingly, patients with syndromes of genomic instability, such as the hereditary non-polyposis colorectal cancer syndromes, have an increased susceptibility to malignant gliomas (Turcot syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genomic instability also appears to have a role in the emergence of recurrences in glioblastoma. MSH6 is a mismatch repair gene and mutations could interfere with the tumor cell's ability to repair DNA damage. Several studies have identified MSH6 mutations in recurrent glioblastomas treated with chemotherapy and radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Migration and invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another cardinal feature of malignant gliomas is their diffuse infiltration of the surrounding neuropil. A considerable amount of effort has been dedicated toward elucidating the mechanisms of glioma cell invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/43\">",
"     43",
"    </a>",
"    ]. This field has been hampered by a lack of adequate animal models. The development of xenograft models of primary human glioblastomas that retain their EGFR status and form invasive tumors is helping to address this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The expression of several extracellular matrix molecules and cell surface receptors may modulate signal transduction pathways and influence invasion and migration in malignant gliomas. These include cytoskeletal proteins; signaling molecules that mediate interactions between the external milieu and the cytoskeleton; cell surface receptors involved in cell migration such as transmembrane adhesion molecules; and components of extracellular matrix, including proteases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Angiogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dramatic sequence of vascular changes occurs in the transition from AA to GBM, a fact that is reflected in the intense, almost ring-like contrast enhancement that surrounds rapidly growing tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/45\">",
"     45",
"    </a>",
"    ]. Malignant gliomas are highly vascular tumors, and the histological presence of microvascular proliferation indicates that the tumor is of high grade. Angiogenic molecules have been found in malignant gliomas, primarily in glioblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/7,45\">",
"     7,45",
"    </a>",
"    ]. The most clearly implicated is vascular endothelial growth factor (VEGF), an endothelial cell mitogen that is expressed most often adjacent to areas of necrosis but not in grade 2 astrocytomas. This suggests that the malignant progression from low-grade astrocytoma to GBM includes an \"angiogenic switch\".",
"   </p>",
"   <p>",
"    VEGF receptors are expressed by tumor endothelial cells, setting up a paracrine loop in which the tumor cells encourage vascular proliferation. The microenvironment is thus of importance in glioblastomas, with regions of neovascularization often surrounding zones of necrosis. Other angiogenic molecules in malignant gliomas include PDGF, with PDGF beta receptor present on endothelial cells, implying a similar paracrine effect of PDGF on endothelial cells.",
"   </p>",
"   <p>",
"    One of the main triggers for tumor angiogenesis is believed to be the physiologic response to hypoxia, which induces increased transcription of the VEGF gene by the hypoxia-inducible factor (HIF) family of transcription factors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. An intriguing hypothesis suggests that thrombosis of small blood vessels, perhaps mediated by tissue factor, induces micronecroses and that these events initiate the hypoxic and angiogenic cascades [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link\">",
"     \"Experimental treatment approaches for malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link\">",
"     \"Overview of angiogenesis inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703196\">",
"    <span class=\"h3\">",
"     Pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above genetic and biological events converge on at least three key regulatory pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/7,49\">",
"     7,49",
"    </a>",
"    ]. Alterations of receptor tyrosine kinases (such as EGFR) that activate ras PI3K signaling are found in nearly 90 percent of glioblastomas and can be collectively thought to lead to hyperproliferation and increased cell survival. Dysregulation of the p53 pathway also occurs in about 90 percent of glioblastomas and leads to effects such as reduced apoptosis. Third, loss of cell-cycle control via disruption of Rb signaling is found in approximately 80 percent of such tumors. Understanding such convergence will be essential to a full biological understanding of glioblastoma and will be critical to designing effective targeted therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSTIC IMPACT OF MOLECULAR ALTERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival of patients with astrocytomas is variable, and cannot be entirely explained by differences in histologic grading or clinical parameters such as age or performance status. Genetic markers may have prognostic relevance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/50\">",
"     50",
"    </a>",
"    ], as illustrated by the following data, but a single clinically useful model that effectively combines such markers has remained elusive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, alterations in EGFR, PTEN, p53 genes and chromosomes 7 and 10 were evaluated by fluorescence in situ hybridization (FISH), reverse transcriptase polymerase chain reaction (RTPCR), and DNA sequencing in 174 patients (63 with anaplastic astrocytoma and 111 with glioblastoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/27\">",
"       27",
"      </a>",
"      ]. In multivariate analysis, PTEN mutations were associated with significantly shorter median survival in patients with anaplastic astrocytoma (4 versus 34 months), while amplification of EGFR was associated with significantly longer survival in older patients (over 60) with glioblastoma.",
"     </li>",
"     <li>",
"      Tumors from 41 patients with GBM who survived &ge;3 years were compared to tumors from 48 patients who survived &le;1.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/51\">",
"       51",
"      </a>",
"      ]. Long-term survivors were less likely to have mdm2 overexpression (45 versus 75 percent), more likely to have accumulation of nuclear p53 (85 versus 56 percent), but not p53 mutations (25 versus 31 percent), and had a significantly lower proliferative rate than short-term survivors.",
"     </li>",
"     <li>",
"      The combined influence of Rb pathway abnormalities (ie, CDKN2A, CDKN2B, RB1 or CDK4) and loss of PTEN on prognosis was studied in a series of 129 patients with GBM [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/52\">",
"       52",
"      </a>",
"      ]. Abnormalities in any of the genes involved in the RB pathway was associated with shorter survival, but the impact was significantly greater in patients whose tumors also had coexisting PTEN loss (median survival 166 versus 437 days for patients with both versus neither abnormality).",
"     </li>",
"     <li>",
"      A series of 220 glioblastomas found that age and performance status were the main predictors of outcome. Multiple molecular markers were studied (loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, amplifications of EGFR, CDK4, and MDM2, CDKN2A homozygous deletions, and p53 expression) but these had limited prognostic importance. Only MDM2 amplification correlated with poor outcome on univariate and multivariate analysis and EGFR amplification with good prognosis on multivariate analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relationship between genetic alterations and prognosis is complex and may be age-dependent. This was illustrated in a series of 140 consecutive patients with GBM treated at a single institution, in which the frequency of TP53 mutations and prognostic influence of TP53 mutations, CDKN2A deletions, EGFR amplification, and loss of chromosome 1p were all dependent upon patient age [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/53\">",
"       53",
"      </a>",
"      ]. These data suggest that pathways to gliomagenesis vary according to age and that studies assessing the prognostic influence of these factors must take patient age into account.",
"     </li>",
"     <li>",
"      The presence of mutations in IDH1 may be an independent prognostic factor, since one study has shown it to be associated with an improved outcome in patients with anaplastic gliomas [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/42\">",
"       42",
"      </a>",
"      ]. Several large studies have observed that the presence of a characteristic mutation in IDH1 or IDH2 has prognostic implications, with a significantly prolonged progression-free survival and overall survival compared with comparable tumors without an IDH mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/14-17\">",
"       14-17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetic subsets of glioblastoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11655?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of oligodendroglial tumors\", section on 'Chemotherapy and deferred RT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chemotherapy responsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular markers are useful to predict a response to chemotherapy in three settings: 1p and 19q loss in oligodendrogliomas, methylguanine-DNA methyltransferase (MGMT) in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    response in glioblastomas, and possibly the EGFR-PI3 kinase pathways in response of glioblastomas to specific EGFR inhibitors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1p 19q deletions &mdash; Allelic loss of chromosome 1p and 19q is a powerful predictor of chemotherapeutic response and longer progression-free and overall survival following chemotherapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      or PCV in patients with anaplastic oligodendrogliomas. Those tumors with 1p and 19q loss in the setting of polysomy of chromosomes 1 and 19 have intermediate prognoses. Testing for 1p and 19q status is now widespread and is used to influence therapeutic decisions. Allelic loss of 1p is also predictive of response to temozolomide patients with grade II oligodendroglial tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical features, pathology, and prognostic factors for oligodendroglial tumors\", section on 'Codeletion 1p/19q'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MGMT &mdash; MGMT is an enzyme that is responsible for DNA-repair following alkylating agent chemotherapy. In the course of tumor development, the MGMT gene may be silenced by methylation of its promoter, thereby preventing repair of DNA damage and increasing the potential effectiveness of chemotherapy. Several clinical studies have indicated that such promoter methylation is associated with an improved survival in patients receiving adjuvant alkylating agent chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/55\">",
"       55",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The clinical implications of the MGMT expression are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link&amp;anchor=H15#H15\">",
"       \"Adjuvant chemotherapy for malignant gliomas\", section on 'MGMT expression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      EGFR-PI3 kinase pathways &mdash; Two papers [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/56,57\">",
"       56,57",
"      </a>",
"      ] reported series of patients with glioblastomas treated with EGFR inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. In contrast to other studies that did not report objective responses [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/58\">",
"       58",
"      </a>",
"      ], these two studies found responses to these agents in patients with recurrent glioblastoma. Furthermore, the reports found associations between response and activation of EGFR itself (one report implicating the wild-type receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/56\">",
"       56",
"      </a>",
"      ] and the other implicating the vIII mutant EGFR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/57\">",
"       57",
"      </a>",
"      ]), as well as between response and whether the PI3 kinase pathway was functionally intact (one report measuring phosphorylated AKT [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/56\">",
"       56",
"      </a>",
"      ] and the other measuring PTEN expression [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14169/abstract/57\">",
"       57",
"      </a>",
"      ]). If responses continue to be documented with these agents, immunohistochemical testing for EGFR and the PI3K pathway may prove useful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gliomas are primary brain tumors that display histological features of glial cells. These are classified according to the 2007 World Health Organization (WHO) system (",
"      <a class=\"graphic graphic_table graphicRef55058 \" href=\"UTD.htm?14/32/14861\">",
"       table 1",
"      </a>",
"      ). The most common malignant (high-grade) gliomas are grade III anaplastic astrocytomas, anaplastic oligodendrogliomas, anaplastic oligoastrocytomas, and grade IV glioblastomas. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are multiple pathways involved in the development of malignant gliomas that appear to involve different molecular events (",
"      <a class=\"graphic graphic_figure graphicRef74978 \" href=\"UTD.htm?2/25/2463\">",
"       figure 1",
"      </a>",
"      ). For example, primary glioblastomas are associated with a variety of molecular changes, most notably epidermal growth factor receptor (EGFR) amplification or overexpression. Alternatively, in so-called \"secondary\" glioblastomas\" and lower-grade gliomas, mutations of the IDH1 and IDH2 genes, a hypermethylation genotype, inactivation of the TP53 tumor suppressor gene (in astrocytomas) and of the CIC gene (in oligodendrogliomas) are characteristic. Inactivation of other tumor suppressor gene are related to cell cycle control and the transition from low-grade to high-grade gliomas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Molecular genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of tumorigenic events are involved in the development of malignant gliomas, including growth factor overexpression, loss of cell cycle control, dysregulation of apoptosis, genomic instability, migration and invasion, and angiogenesis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Molecular biology'",
"      </a>",
"      above.) Other events are associated with the recurrence of malignant gliomas following standard therapy, including mismatch repair defects and genomic hypermutation.",
"     </li>",
"     <li>",
"      The survival of patients with malignant gliomas can vary substantially. Identification of specific molecular alterations may be valuable both in assessing prognosis and response to treatment. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognostic impact of molecular alterations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Pathology and genetics of tumours of the nervous system. In: World Health Organization Classification of Tumours of the Nervous System, Editorial and Consensus Conference Working Group, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon, France 2007.",
"    </li>",
"    <li>",
"     Ironside JW, Moss TH, Louis DN, et al. Diagnostic Pathology of Nervous System Tumours, Churchill Livingstone, London 2002.",
"    </li>",
"    <li>",
"     Reifenberger G, Kros JM, Louis DN, Collins VP. Oligodendroglioma; Anaplastic oligodendroglioma. In: World Health Organization Histological Classification of Tumours of the Central Nervous System, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon, France 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/4\">",
"      Kozak KR, Mahadevan A, Moody JS. Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 2009; 11:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/5\">",
"      Louis DN, Pomeroy SL, Cairncross JG. Focus on central nervous system neoplasia. Cancer Cell 2002; 1:125.",
"     </a>",
"    </li>",
"    <li>",
"     James CD, Louis DN, Cavenee WK. Molecular biology of central nervous system tumors. In: Cancer: Principles and Practice of Oncology, 8th, DeVita VT, Lawrence TS, Rosenberg SA (Eds), Lippincott-Raven, Philadelphia 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/7\">",
"      Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/8\">",
"      Stemmer-Rachamimov AO, Louis DN, Nielsen GP, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004; 64:3718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/9\">",
"      Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005; 8:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/10\">",
"      Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64:7011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/11\">",
"      Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/12\">",
"      Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/13\">",
"      Kloosterhof NK, Bralten LB, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 2011; 12:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/14\">",
"      Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/15\">",
"      Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27:4150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/16\">",
"      Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27:5743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/17\">",
"      van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/18\">",
"      Camelo-Piragua S, Jansen M, Ganguly A, et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 2010; 119:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/19\">",
"      Horbinski C, Kofler J, Kelly LM, et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009; 68:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/20\">",
"      Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/21\">",
"      Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/22\">",
"      Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/23\">",
"      Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/24\">",
"      Fujisawa H, Kurrer M, Reis RM, et al. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol 1999; 155:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/25\">",
"      Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/26\">",
"      Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/27\">",
"      Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006; 106:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/28\">",
"      Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/29\">",
"      Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66:9852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/30\">",
"      Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/31\">",
"      Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003; 62:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/32\">",
"      Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/33\">",
"      Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/34\">",
"      Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/35\">",
"      Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006; 24:4746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/36\">",
"      Snuderl M, Eichler AF, Ligon KL, et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 2009; 15:6430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/37\">",
"      Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7:839.",
"     </a>",
"    </li>",
"    <li>",
"     Cavenee WK, Furnari FB, Nagane M, et al. Diffusely infiltrating astrocytomas. In: World Health Organization Classification of Tumours of the Central Nervous System, Kleihues P, Cavenee WK (Eds), Lyon IARC/WHO, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/39\">",
"      Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52:3213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/40\">",
"      Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007; 13:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/41\">",
"      Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006; 66:3987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/42\">",
"      Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27:5874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/43\">",
"      Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/44\">",
"      Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006; 12:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/45\">",
"      Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 2003; 138:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/46\">",
"      Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004; 84:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/47\">",
"      Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/48\">",
"      Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/49\">",
"      Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/50\">",
"      Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 2010; 9:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/51\">",
"      Burton EC, Lamborn KR, Forsyth P, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002; 8:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/52\">",
"      B&auml;cklund LM, Nilsson BR, Goike HM, et al. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 2003; 9:4151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/53\">",
"      Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004; 10:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/54\">",
"      Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/55\">",
"      Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26:4189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/56\">",
"      Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005; 97:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/57\">",
"      Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14169/abstract/58\">",
"      Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5223 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14169=[""].join("\n");
var outline_f13_53_14169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H703112\">",
"      Cell of origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Formation of astrocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Transition to malignant glioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Genetic subsets of glioblastoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Formation of oligodendroglioma and oligoastrocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Genetic subsets of anaplastic oligodendroglioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Molecular biology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Growth factor overexpression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Loss of cell cycle control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Dysregulation of apoptosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Genomic instability and malignant progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Migration and invasion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Angiogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H703196\">",
"      - Pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSTIC IMPACT OF MOLECULAR ALTERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chemotherapy responsiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5223\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5223|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/25/2463\" title=\"figure 1\">",
"      Genetic pathways glioblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5223|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/11/16566\" title=\"picture 1\">",
"      Anaplastic astrocytoma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/24/25990\" title=\"picture 2\">",
"      GBM Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5223|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/32/14861\" title=\"table 1\">",
"      WHO brain tumor classification by histology and grade",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=related_link\">",
"      Clinical features, pathology, and prognostic factors for oligodendroglial tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11655?source=related_link\">",
"      Treatment of oligodendroglial tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_53_14170="Risk factors for graft failure in kidney transplantation";
var content_f13_53_14170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for graft failure in kidney transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14170/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14170/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14170/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/53/14170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/53/14170/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/53/14170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite significant improvements in one year kidney allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/1\">",
"     1",
"    </a>",
"    ], the rate of chronic graft loss after the first year remains substantial and may not have improved over the last decade. As an example, a 2004 study that analyzed first renal transplants performed between 1995 and 2000 found that, despite a reduction in acute rejection rates, there was no improvement over the last 10 years in long-term allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/2\">",
"     2",
"    </a>",
"    ]. Despite this, the rate of decline in kidney allograft function appears to have slowed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/3\">",
"     3",
"    </a>",
"    ], suggesting that improved results relating to long-term allograft survival are possible.",
"   </p>",
"   <p>",
"    Allograft survival rates also vary among different ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/4\">",
"     4",
"    </a>",
"    ]. This may be explained in part by the presence of a disproportionately higher number of risk factors among certain patient populations and differences in access to health care [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/5-10\">",
"     5-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion will review the determinants of short-term and long-term graft survival. However, this distinction is, to some degree, arbitrary since most factors can affect both. As an example, any short-term event that predisposes to episodes of acute rejection will then lead to a greater likelihood of chronic graft loss. In addition, many of these factors influence each other, such as HLA mismatching that may increase the risk of acute renal rejection and subsequent premature allograft failure. A discussion of patient survival after renal transplantation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SHORT TERM SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of graft loss has traditionally been divided into an early, high-risk period and a later period of constant low risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A major improvement in renal allograft survival in the past 20 years has been the relative elimination of the early risk period.",
"   </p>",
"   <p>",
"    A number of factors have been shown to influence short-term graft survival. These include delayed allograft function, HLA antibodies, type of donor kidney, donor illness, medical center factors, and other factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Delayed allograft function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of delayed graft function has a major adverse impact upon both short and long-term allograft survival. In one single center study of 518 patients, multivariate analysis found that delayed graft function was the principal factor underlying kidney survival at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/13\">",
"     13",
"    </a>",
"    ]; by comparison, acute rejection, HLA matching, degree of sensitization, and re-transplantation did not significantly affect short-term survival.",
"   </p>",
"   <p>",
"    Issues surrounding delayed allograft function and long-term allograft survival are discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Tissue injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     HLA antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that the presence of HLA antibodies is associated with an increased risk of early graft loss. Based upon data from nearly 5000 patients, the frequency of HLA antibodies was 21 percent among renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/14\">",
"     14",
"    </a>",
"    ]. Over 2000 patients were followed prospectively, with 91 grafts failing and 34 deaths. The risk of allograft failure at one year was significantly higher among those with HLA antibodies (6.6 versus 3.3 percent), as well as among those who developed such antibodies de novo (8.6 versus 3 percent).",
"   </p>",
"   <p>",
"    In addition, such antibodies place patients awaiting transplantation at a significant disadvantage, as their waiting time for an allograft is markedly prolonged and they are at increased risk of both delayed graft function and rejection in the perioperative period. Some of these issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=see_link\">",
"     \"HLA matching and graft survival in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of HLA antibodies also has an adverse effect upon long-term allograft survival. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'HLA matching'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type of kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally acknowledged that not all kidneys for transplantation are created equal. Such organs have long been characterized by donor source whether living or deceased. Living donor transplants have a greater short-term survival rate than deceased donor kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Allograft survival rates for living donor transplants and deceased donor non-expanded criteria donors are 98 versus 96 percent at three months and 96 versus 92 percent at one year, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/16\">",
"     16",
"    </a>",
"    ]. A graft survival benefit with living transplants is also observed with second allografts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/17\">",
"     17",
"    </a>",
"    ]. This difference reflects the optimal circumstances surrounding living-related donation compared with the potentially injurious effect of deceased donor donation. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Tissue injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Deceased donors are categorized as standard criteria donors (SCD) or expanded criteria donors (ECD). However, the utility of this rudimentary classification is limited by the presence of substantial overlap in outcomes and kidney quality since the ECD category is broad and nonuniform, and includes kidneys that are likely to have different outcomes. As an example, the ECD category would include both a perfectly healthy 60-year-old with a normal serum creatinine and a 55-year-old with diabetes, hypertension, and a creatinine of 1.6",
"    <span class=\"nowrap\">",
"     mg/dl.",
"    </span>",
"   </p>",
"   <p>",
"    By contrast, a central feature of a more recently proposed allocation system is the kidney donor profile index (KDPI), which is a continuous rather than a dichotomous index of the quality of donor kidneys from the highest quality, with the longest projected functional lifetime after transplant, to the lowest quality, with the shortest projected functional lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/18\">",
"     18",
"    </a>",
"    ]. The more granular KDPI, based solely on donor characteristics, combines a variety of donor risk factors for graft failure (",
"    <a class=\"graphic graphic_table graphicRef88376 \" href=\"UTD.htm?4/15/4347\">",
"     table 1",
"    </a>",
"    ) into a single number. In one study that used the KDPI (or KDRI, Kidney Donor Risk Index) to classify deceased donor kidney, the highest quintile (with highest risk for graft failure or lowest projected survival), had a calculated five-year survival of 63 percent compared with those in the lowest two risk quintiles, which had a projected five-year survival of 82 and 79 percent, respectively. The KDPI system overlapped with the",
"    <span class=\"nowrap\">",
"     ECD/SCD",
"    </span>",
"    system in that the percentage of ECD kidneys rose with increasing risk quintile. However, 32 percent of ECD kidneys study had KDRI less than the 85th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H567502624\">",
"    <span class=\"h3\">",
"     Standard criteria donor kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard criteria donor kidneys (SCD) are defined by conventional brain death criteria. These kidneys have the highest short-term survival rates (approximately 91 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/16\">",
"     16",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H567502638\">",
"    <span class=\"h3\">",
"     Expanded criteria donor kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expanded Criteria donor kidneys (ECD) are brain dead donors that are further defined by an increase of 1.7 in relative risk of premature graft failure within the first year post-transplant. Such kidneys derive from donors over the age of 60 as well as those with a history of hypertension or stroke as the cause of death. ECD kidneys are associated with decreased short-term allograft survival, particularly among those undergoing retransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Overall graft survival correlates inversely with decreasing quality of donor kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/23\">",
"     23",
"    </a>",
"    ], although the exact definition of quality is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, excellent survival has been reported with the transplantation of kidneys from older donors (greater than 60 years of age) with histologic criteria indicative of an increased mass of functioning nephrons [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/25\">",
"     25",
"    </a>",
"    ]. This was shown in a prospective cohort study in which similar allograft survival at nearly two years was reported in recipients of such kidneys versus those who received kidneys from donors 60 years of age or younger [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/25\">",
"     25",
"    </a>",
"    ]. Nevertheless, overall outcomes with ECD kidneys remain superior to those observed with dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H567502631\">",
"    <span class=\"h3\">",
"     Donation after cardiac death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donation after cardiac death (DCD) has become a focus of interest because of a growing body of data showing acceptable allograft survival of such organs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of United Kingdom (UK) transplant registry data showed that among 6490 deceased-donor kidney transplants, there was no difference in the three-year graft survival between DCD (n= 1768) and brain-death (n = 4127) kidneys, after adjusting for donor age, donor hypertension, donor serum creatinine , recipient age, cause of renal disease, HLA mismatch, transplant center and cold ischemia time [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/29\">",
"       29",
"      </a>",
"      ]. However among DCD but not brain-death donor kidneys, cold ischemia &gt;24 hours compared with &gt;12 hours, was associated with decreased graft survival (HR 2.36 95% CI 1.39-4.02).",
"     </li>",
"     <li>",
"      In another study, the outcomes of transplantation were reported from more than 250 DCD donors at a single institution over a 30-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/28\">",
"       28",
"      </a>",
"      ]. The recipients were divided into four groups according to the year of transplant. The overall allograft survival rate at one year was 80 percent. Low severity pre-arrest acute renal failure did not appear to preclude DCD donation, although pulsatile perfusion may be advisable in this situation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not clear whether DCD kidneys from older donors have worse outcomes compared with kidneys from brain-death donors of a comparable age. In one small study, allografts from DCD donors over age 65 had a lower GFR at one year and a trend toward a lower five-year graft survival compared with younger DCD donors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/31\">",
"     31",
"    </a>",
"    ]. However there was no difference in graft survival when kidneys with extensive vascular pathology were excluded from the analysis. Additionally, in the study of UK registry data cited above, there was no difference in graft loss for DCD donors older than 60 years compared with brain-death donors in the same age group [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Center effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, Europe, and Canada, a marked center effect with respect to short-term graft survival has been reported that cannot be explained by different clinical features of enrolled patients. This appears to be a consistent finding that has been observed over the last few decades, a period of increasingly effective immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Possible underlying reasons include center volume and differences in long-term patient management experience. Center-specific data are compulsorily reported to USRDS as public information and are available online at",
"    <a class=\"external\" href=\"file://www.ustransplant.org/\">",
"     www.ustransplant.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H567502790\">",
"    <span class=\"h2\">",
"     Donor age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing donor age is associated with inferior survival of allografts from deceased donors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/29,36\">",
"     29,36",
"    </a>",
"    ]. In an analysis of 6490 deceased donor kidney transplants identified from the UK transplant registry, compared with donor age less than 40 years, donor age older than 60 was associated with increased risk of graft failure (HR 2.35, 95% CI 1.85-3.00) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Donor illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deceased donor allograft survival may also vary by the cause of donor death",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    history of specific comorbid illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/15,37\">",
"     15,37",
"    </a>",
"    ]. As an example, kidneys transplanted from stroke victims had lower one-year allograft survival rates than seen overall with deceased donor renal transplantation (79 versus 84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dialysis and preemptive transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early allograft survival may vary with the use of maintenance dialysis and perhaps the type of dialysis prior to transplantation. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=see_link\">",
"     \"Dialysis issues prior to and after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LONG-TERM SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of clinical risk factors for long-term allograft failure has been provided by several studies performed in the current immunosuppressive era [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In the ALERT trial, for example, 2000 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    or placebo and followed for five to six years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/38\">",
"     38",
"    </a>",
"    ]. In the placebo group, allograft loss was noted in 137 patients, which was principally caused by chronic allograft nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .) With multivariate analysis, independent baseline risk factors for enhanced risk of allograft loss included increased serum creatinine concentration (RR of 3.12 per every increase of 100 &micro;M), proteinuria (RR of 1.6 per every 1",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    and pulse pressure (RR 1.12 per every increase of 10 mmHg).",
"   </p>",
"   <p>",
"    An additional possible marker for enhanced risk of poor long-term survival is decreased renal function at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one study, there was a progressive decline in allograft half-life for each incremental increase in the serum creatinine concentration at six months and at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact mechanisms responsible for the pathogenesis of chronic allograft dysfunction leading to long-term graft loss are unknown. Both alloantigen dependent and independent factors are thought to play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Long-term graft survival is generally measured in terms of the half life, which is defined as the time beyond the first year posttransplant at which 50 percent of grafts are no longer functioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Alloantigen-dependent factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rejection and allograft loss is more likely to develop in patients with a history of acute rejection, a greater degree of HLA mismatching, infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. These observations are consistent with an important role for immunologic or alloantigen dependent injury in the subsequent development of chronic allograft dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Episodes of acute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of acute rejection episodes are more likely to have late allograft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. This was shown in a study of 63,045 primary renal recipients, in which an acute rejection episode in 1996 to 1997 was associated with a 5.2 fold increased risk for chronic allograft nephropathy compared with no rejection in a reference group from 1988 to 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     HLA matching",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased degree of HLA antigen mismatching is associated with a greater risk of chronic graft loss, presumably due to ongoing specific immunologic injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=see_link\">",
"     \"HLA matching and graft survival in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When organ allocation is based upon HLA typing, one concern is the effect of cold ischemia time upon long-term survival. The beneficial effect of HLA matching appears to generally outweigh the detrimental effect of prolonging the cold ischemia time in transported kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/50\">",
"     50",
"    </a>",
"    ]. The current registry data indicate that the five year graft survival of six antigen matched cadaver kidneys is the same regardless of whether the kidneys undergo 3 or 36 hours of cold ischemia.",
"   </p>",
"   <p>",
"    However, a deleterious effect of prolonged cold ischemia time becomes evident in recipients of mismatched grafts. A stepwise reduction of 1 to 2 percent in survival has been observed in association with incremental 12 hour increases in cold ischemia time. The adverse effect of cold ischemia can also be observed when allograft survival is compared between the recipients of a first deceased donor transplanted and the recipient of the second donor kidney transplanted (mean of 19.9 versus 25.6 hours cold ischemia time) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/51\">",
"     51",
"    </a>",
"    ]. The five and 10 year survival was 72 and 55 percent for the first kidney transplanted, respectively, compared with 65 and 40 percent for the second kidney transplanted.",
"   </p>",
"   <p>",
"    Insight into the relative contributions to allograft survival of HLA matching and cold ischemia time is also provided by examining the graft survival rates of living-unrelated kidneys. Graft survival rates of kidneys donated by a spouse are very similar to those of kidneys donated by family members with a one haplotype mismatch (half-life of 12 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. If HLA mismatching were the only factor affecting graft survival, the living unrelated grafts should have poorer long-term survival, possibly in the range of randomly matched cadaver grafts (which generally have about three HLA mismatches and an average half-life of 8.4 years).",
"   </p>",
"   <p>",
"    Thus, both cold ischemia time and HLA matching exert important effects upon long-term graft survival. However, six antigen matching completely overcomes the effect of ischemia, and lesser degrees of matching (even in the presence of ischemia) yield superior results than zero antigen matched kidneys. Changes in allograft immunogenicity induced by tissue injury prior to death in cadaveric transplants also may contribute to the lower long-term survival with cadaveric as opposed to living donor kidneys (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Tissue injury'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies against HLA class I (A,B,C) or class II (DR, DQ) are found in subjects who have been immunized to these glycoproteins by pregnancy, blood transfusion, or a prior HLA mismatched allograft. Highly sensitized patients have a decreased statistical chance of being transplanted because of the high likelihood of a positive pretransplant crossmatch [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increases in sensitization to lymphocyte antigens, as measured by the panel reactive antibody (PRA) status, incrementally augment the risk of graft loss. Five year deceased donor non-ECD allograft survival rates in the 2007 Scientific Registry of Transplant Recipients annual report were [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      71 percent for patients with a PRA of zero to 9 percent",
"     </li>",
"     <li>",
"      69 percent with a PRA of 10 to 79 percent",
"     </li>",
"     <li>",
"      69 percent with a PRA of &gt;80 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is increasingly appreciated that the presence of preformed HLA donor-specific antibodies (DSA) has an adverse effect upon allograft outcomes. Using very sensitive HLA-specific assays, allograft survival at eight years was evaluated among 43 patients with and 194 patients without preformed DSA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/57\">",
"     57",
"    </a>",
"    ]. Allograft survival was 68 versus 77 percent for those with and without DSA, respectively, while the incidence of antibody mediated rejection was ninefold higher in those with preformed DSA.",
"   </p>",
"   <p>",
"    Limited data suggest that sensitization may, in some cases, represent non-HLA immunity, with increased levels associated with decreased survival. As an example, a retrospective study of over 4000 recipients of HLA-identical sibling transplants evaluated the long-term survival in association with panel reactive antibody (PRA) levels [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/58\">",
"     58",
"    </a>",
"    ]. Given that these transplants were between HLA-identical siblings, the presence of PRA was thought to represent antibodies against HLA antigens not found in the transplanted kidney. However, ten year survival was highest among those with no panel reactive antibodies (72 percent) versus those with either 1 to 50 percent PRA (63 percent) or greater than 50 percent PRA (56 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/58\">",
"     58",
"    </a>",
"    ]. This suggests that non-HLA transplantation immunity, as detected by PRA, may have a role in long-term allograft survival.",
"   </p>",
"   <p>",
"    The importance of non-HLA immunity was further supported by a two year prospective study of 2231 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/59\">",
"     59",
"    </a>",
"    ]. At two years, allograft survival was significantly higher among the 1,781 patients without HLA antibodies (93 versus 85 percent). Outcome correlated better with the results with cytotoxicity testing versus ELISA or HLA beads, suggesting that the presence of non-HLA antibodies correlates with decreased survival.",
"   </p>",
"   <p>",
"    Although mismatching at the rhesus (Rh) blood group antigen is not considered a risk factor for allograft rejection, a multivariate analysis of United Network of Organ Sharing (UNOS) data found that Rh incompatibility may confer worse long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/60\">",
"     60",
"    </a>",
"    ]. In this study, Rh identity between the recipient and donor was significantly related to better graft outcome (risk ratio 0.43).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Alloantigen independent factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clues from clinical transplant databases support the hypothesis that inadequate renal mass, prior and ongoing tissue injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/61\">",
"     61",
"    </a>",
"    ], posttransplant hypertension, hyperlipidemia, a more marginal kidney, and recurrent or de novo glomerular disease contribute to chronic allograft dysfunction and poor long-term kidney survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other substantial risk factors for allograft failure, particularly over the long term, are calcineurin-inhibitor nephrotoxicity and death of the transplant recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/63\">",
"     63",
"    </a>",
"    ]. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tissue injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allograft injury plays a major role in both short- and long-term graft function, as well as in the induction of renal allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/64\">",
"     64",
"    </a>",
"    ]. Such injury may be induced by different events, including brain death, cold ischemia time, ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reperfusion, and infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain death &mdash; Brain death resulting from trauma or catastrophic intracranial hemorrhage is associated with a variety of adverse effects upon donor organs prior to transplantation. Under such circumstances, allograft tissue becomes \"primed\" and recipient T cell activation by donor alloantigen is more likely to occur [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/65\">",
"       65",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Among patients with brain death, intracranial pressure rises due to cerebral edema, which results in compression of brain tissue and subsequent venous congestion and increasing brain turgor. Massive release of catecholamines then ensues, which causes profound vasoconstriction and endothelial injury [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/66\">",
"       66",
"      </a>",
"      ]. Injury-induced inflammation also causes upregulation of adhesion molecules and class II MHC on renal allograft endothelium [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. In addition, a procoagulant state results from endothelial activation coupled with release of cytokines, complement activation, and depletion of tissue plasminogen activator [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/69\">",
"       69",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other endocrine aberrations resulting from brain death include the initial release of anterior pituitary hormones which leads to a subsequent reduction in the levels of circulating thyroid hormone, cortisol, insulin and antidiuretic hormone (vasopressin). Diabetes insipidus rapidly occurs, and cardiac arrhythmias and rapid fluctuations in blood pressure are common. Such factors may obviously adversely affect the function and integrity of the kidney.",
"     </li>",
"     <li>",
"      Ischemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reperfusion injury &mdash; Ischemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reperfusion injury is thought to be a critical risk factor for both early delayed graft function and late allograft dysfunction. The dominant cause of delayed graft function is postischemic acute tubular necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/70\">",
"       70",
"      </a>",
"      ]. The incidence of this complication increases when the cold ischemia time exceeds 18 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/71\">",
"       71",
"      </a>",
"      ], particularly with older donor kidneys [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/22\">",
"       22",
"      </a>",
"      ]. There is some evidence that the HTK and University of Wisconsin solutions provide similar patient and kidney (although not pancreas) allograft survival rates. Cold ischemia time alone is also a principal factor underlying long-term allograft survival [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=see_link\">",
"       \"Differential diagnosis of renal allograft dysfunction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Preservation of the allograft with pulsatile preservation may improve long-term survival compared with that observed with simple cold storage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/27/437?source=see_link\">",
"       \"Deceased and living donor renal allograft recovery\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Injury alone may not influence graft survival in the absence of rejection, as shown in some [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/72-74\">",
"       72-74",
"      </a>",
"      ], but not all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/75\">",
"       75",
"      </a>",
"      ]. As an example, among over 9000 kidneys retrieved and analyzed from the United Kingdom national transplant database, damage recognized at organ retrieval or placement was not significantly associated with survival at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/74\">",
"       74",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The circumstances surrounding organ removal, storage, and engraftment may increase graft immunogenicity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/67,69,70,76-78\">",
"       67,69,70,76-78",
"      </a>",
"      ]. Such factors include the upregulation of MHC antigens and triggering of the cytokine-adhesion molecule cascade. These factors may ultimately influence the development of chronic allograft dysfunction. As an example, blockade of costimulatory pathways can ameliorate organ dysfunction in a rat model of",
"      <span class=\"nowrap\">",
"       ischemia/reperfusion",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/79\">",
"       79",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are limited data concerning the relative degree of injury with grafts harvested from deceased donors with or without a heartbeat. Those from donors without a heartbeat or deceased cardiac donors (DCD) are thought to be associated with some degree of irreversible damage, thereby leading to relatively poor long-term allograft survival. However, some data suggest that outcomes may be satisfactory. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Type of kidney donor'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cytomegalovirus &mdash; The presence of seropositivity to CMV predisposes patients to both acute and chronic graft loss. Seronegative recipients of seronegative grafts appear to experience a 10 percent higher graft survival than recipients of seropositive grafts. This difference may be due to infection-induced cytokine activation, which in turn may promote graft injury [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/80\">",
"       80",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Graft survival rates are also affected by pretransplant",
"      <span class=\"nowrap\">",
"       recipient/donor",
"      </span>",
"      cytomegalovirus serostatus and whether prophylaxis was administered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"       \"Cytomegalovirus infection in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Inadequate renal mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation of inadequate renal mass may be associated with a higher risk of renal graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/81\">",
"     81",
"    </a>",
"    ]. Data supporting this hypothesis in humans is based upon the observation of lesser graft survival rates with older and very young donor kidneys, recipients in whom the donor kidney has disproportionately fewer nephrons, and ratio of donor kidney weight to recipient weight:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Old and very young donor kidneys &mdash; Old and very young kidneys have relatively decreased numbers of functioning nephrons, and survive less well when transplanted. In addition to fewer nephrons, other factors inherent to an older kidney may also influence overall allograft survival [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disproportionately fewer nephrons &mdash; Large sized recipients place a large physiologic demand on the transplanted kidney. This increased demand upon relatively \"insufficient\" numbers of transplanted nephrons may be a factor in the lower long-term graft survival rate observed among some patients who weigh more than 100 kg [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several different studies have evaluated the relationship between allograft",
"      <span class=\"nowrap\">",
"       function/survival",
"      </span>",
"      and the ratio of donor kidney weight to recipient weight [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/84-90\">",
"       84-90",
"      </a>",
"      ]. In the largest such study of 1189 kidney transplant recipients, the ratio of the weight of the kidney to the weight of the recipient (KwRw ratio) was evaluated with respect to the risk of proteinuria, glomerulosclerosis, and allograft failure [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/90\">",
"       90",
"      </a>",
"      ]. A low KwRw ratio (less than 2.3",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      was associated with an increased risk of glomerulosclerosis (17 versus 4.7 percent), proteinuria, and long-term allograft loss (1.55 fold increased risk [1.01 to 2.12, 95% CI] beginning two years post-surgery). The magnitude of risk for decreased allograft survival with a low KwRw ratio is approximately the same as the risk due to an acute rejection episode or delayed allograft function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Drug noncompliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncompliance is one of the more important risk factors for renal graft loss over the long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/91-94\">",
"     91-94",
"    </a>",
"    ]. An accurate assessment of the frequency of noncompliance and its contribution to allograft loss is difficult because of the wide variability in study design and results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36517?source=see_link\">",
"     \"Psychiatric aspects of organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Posttransplant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term allograft and patient survival may be negatively influenced by posttransplant hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. A multivariate analysis found that, after adjustment for baseline renal function, the relative risk of allograft failure was 1.30 for each 10 mmHg increase in the mean arterial pressure measured at one year after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=see_link\">",
"     \"Hypertension after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia is an established risk factor for arteriosclerosis and coronary artery disease in all patients, including cardiac and renal transplant recipients; it may also result in increased graft loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Recurrent or de novo glomerular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent or de novo glomerular disease results in significantly lower long-term allograft survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study evaluated the outcomes of nearly 5000 renal transplants followed in the Renal Allograft Disease Registry, 167 of which had clinical and biopsy evidence of recurrent or de novo glomerular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/100\">",
"       100",
"      </a>",
"      ]. The relative risk for allograft failure was 1.9 for those with glomerular disease. At five years, patients with glomerular disease had a much higher rate of allograft failure (60 versus 32 percent in those without glomerular disease).",
"     </li>",
"     <li>",
"      Among 1505 renal transplant recipients with end-stage renal disease due to glomerulonephritis, allograft loss as a result of biopsy-proven recurrent glomerulonephritis was observed in 52 patients (3.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/101\">",
"       101",
"      </a>",
"      ]. The 10-year incidence of graft loss because of recurrent disease was estimated to be 8.4 percent (95 percent CI 5.9 to 12.0 percent); recurrent glomerulonephritis was the third most common cause of allograft loss among these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The improved long-term survival observed in well-matched HLA grafts may also be less apparent in transplant recipients with a primary glomerular disease. In one report of 60 patients in whom a HLA-identical living related donor transplant had been performed, allograft survival was correlated with the original renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/102\">",
"     102",
"    </a>",
"    ]. Among the 33 patients with an underlying glomerulonephritis, the 5, 10, and 20 year graft survival was 88, 70, and 63 percent, respectively; by comparison,",
"    <strong>",
"     no",
"    </strong>",
"    case of graft loss was observed among the remaining patients with nonglomerular renal diseases. Recurrent disease appeared to be the principal cause of graft loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Type of kidney donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Living donor kidney transplants have a greater long-term graft survival rate than deceased donor kidneys (primarily from brain dead donors). In the 2009 SRTR report, for example, the five-year allograft survival rates for living donor, non-extended criteria deceased donor, and extended criteria deceased donor kidneys were 81, 72, and 57 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A graft survival benefit with living transplants is also observed with second allografts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/17\">",
"     17",
"    </a>",
"    ]. This difference reflects the optimal circumstances surrounding living-related donation compared with the potentially injurious effect of cadaveric donation. In addition, decreasing allograft survival correlates with decreasing quality of the cadaveric kidney.",
"   </p>",
"   <p>",
"    There is also an increasing body of data suggesting that long-term survival with a deceased cardiac donor (DCD) kidney appears to be adequate, particularly as reported from Japan. In one study from Japan, for example, the overall graft survival rates at 5 and 10 years were 72, and 53 percent respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the last several years, there has also been a steady improvement in outcome with DCD donor kidneys from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/28,104-108\">",
"     28,104-108",
"    </a>",
"    ]. In the UNOS database, the outcome of DCD donor kidney transplantation at five years post-transplant, both in terms of patient (81 percent) and graft (67 percent) survival, is not significantly different from that of kidneys from donors deceased after brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Additional factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gene polymorphisms &mdash; Variations in the ability to mount an effective immune response against the allograft as well as differences in underlying factors affecting allograft fibrosis represent alloantigen independent factors that may affect graft survival:",
"     </li>",
"     <li>",
"      Caveolin-1 (CAV1) appears to have an important role in the development of organ fibrosis. A retrospective study found that a CAV1 polymorphism is associated with an increased risk of allograft failure, which is closely related to allograft fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study evaluated allograft survival among 1227 renal transplant recipients who were screened for the presence of a 32 base pair deletion for the chemokine receptor 5 (CCR5) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/110\">",
"       110",
"      </a>",
"      ]. The intact molecule is a cell surface receptor for several chemokines as well as the human immunodeficiency virus. Patients who were homozygous for this deletion (which results in a nonfunctional receptor and occurs in approximately 1 percent of Caucasian populations in Europe and North America) had significantly longer allograft survival than those who were non-homozygous (90 versus 25 percent survival at 20 years as predicted by Kaplan-Meier survival plots).",
"     </li>",
"     <li>",
"      The relationship between clinical outcome and complement 3 (C3) allotypes is unclear. There are two C3 allotypes, F for fast and S for slow, which appear to have an influence on inflammatory disorders. One study found that allograft survival was significantly higher with",
"      <span class=\"nowrap\">",
"       C3F/F",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       C3F/S",
"      </span>",
"      donor kidneys, with the benefit unique to those recipients without the C3F allele [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/111\">",
"       111",
"      </a>",
"      ]. By comparison, a much larger study found no association between improved survival and the different forms of C3 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultrasonographic resistance index &mdash; An increased resistance index as determined by Doppler ultrasonography is another factor that has been associated with markedly decreased allograft survival. A single center German study evaluated 601 stable patients at least three months after successful renal transplant surgery; all patients were then followed for at least three years [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/113\">",
"       113",
"      </a>",
"      ]. A resistance index of greater than 80 percent, which nonspecifically reflects increased vascular resistance, was seen in 20 percent of patients. These patients had a multivariate determined relative risk of graft loss of 9.1 (95% CI 6.6-12.7).",
"      <br/>",
"      <br/>",
"      Confirmation in additional centers and further study to correlate a high resistance index with underlying histology are both required to determine the prognostic role of screening Doppler ultrasonography [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperhomocysteinemia &mdash; Elevated homocysteine levels are associated with decreased allograft survival. A prospective study of 733 renal transplant recipients compared baseline fasting plasma total homocysteine levels to renal allograft survival during a median follow-up of 6.1 years [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/115\">",
"       115",
"      </a>",
"      ]. After statistical adjustment, elevated levels of homocysteine (&ge;12",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      were associated with an increased risk of allograft loss (hazard ratio 1.63, 95% CI 1.09-2.44) and mortality (hazard ratio 2.44, 95% CI 1.45-4.12). A randomized control trial (FAVORIT,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic Acid",
"      </a>",
"      for Vascular Outcomes Reduction In Transplant recipients) did not show a benefit for high dose B complex vitamin supplementation however [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Proteinuria &mdash; The presence of proteinuria (including levels of less than one",
"      <span class=\"nowrap\">",
"       gram/day)",
"      </span>",
"      are predictors of long-term allograft loss [",
"      <a class=\"abstract\" href=\"UTD.htm?13/53/14170/abstract/38,117,118\">",
"       38,117,118",
"      </a>",
"      ]. This correlation likely reflects the presence of ischemia-reperfusion lesions, ongoing",
"      <span class=\"nowrap\">",
"       immunologic/nonimmunologic",
"      </span>",
"      allograft injuries, and other pathogenic processes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14813848\">",
"    <span class=\"h1\">",
"     OPTOMIZING OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre-, peri-, and posttransplantation factors affect graft survival after transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretransplantation &mdash; The goal of the transplant team is to engraft as many recipients as possible while minimizing complications that impact graft and patient survival. Unfortunately, such goals may be at variance. As an example, the increased use of expanded criteria donors can increase the number of transplants performed while negatively impacting graft survival. Thus, a key part of the organ selection process potentially is to balance such variables by providing secondary benefits such as reducing waiting time for those who agree to receive such grafts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"       \"Organ sharing in kidney transplantation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Transplant programs should also consider patient selection criteria as important predictors of outcome. For example, transplanting a higher proportion of &ldquo;high risk&rdquo; candidates will adversely impact survival rates. Such case mix-adjusted information is tracked by both the United Network for Organ Sharing (UNOS) and Centers for Medicare and Medicaid Services (CMS) and is also available online to all members of the public at",
"      <a class=\"external\" href=\"file://www.ustransplant.org/\">",
"       www.ustransplant.org",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Peritransplantation &mdash; Minimizing cold and warm ischemia time is an attractive target for reducing the risk of delayed graft function and decreased graft survival. In truth, delays in organ allocation and transportation are logistic realities that programs often have little control over.",
"     </li>",
"     <li>",
"      Posttransplantation &mdash; Careful titration of immunosuppression is essential following transplantation. Minimizing rejection rates must be balanced against the risk of infection. Addressing comorbidities such as hypertension and dyslipidemia may improve long term outcomes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=see_link\">",
"       \"Hypertension after renal transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link\">",
"       \"Lipid abnormalities after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18182802\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are multiple determinants of short-term and long-term graft survival; most factors can affect both. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major factors that decrease short-term graft survival include delayed allograft function and the presence of HLA antibodies. In addition, living donor transplants have a greater short-term survival rate than deceased donor kidneys. Expanded criteria donor kidneys (ie, from brain dead donors over the age of 60 or with a history of hypertension or stroke as the cause of death) are also associated with decreased short-term graft survival. Donor illness, cytomegalovirus seropositivity and factors related to the transplant medical center may also play a role. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Short term survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early allograft survival may vary with the use of maintenance dialysis and perhaps the type of dialysis prior to transplantation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Dialysis and preemptive transplantation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=see_link\">",
"       \"Dialysis issues prior to and after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Late allograft failure is increased in patients with delayed graft function, HLA mismatching, cold ischemia time, the development of anti-HLA antibodies, and inadequate immunosuppressive therapy. The beneficial effect of HLA matching outweighs the detrimental effect of prolonging the cold ischemia time in transported kidneys. Preformed HLA donor-specific antibodies are associated with decreased allograft survival and may represent non-HLA immunity in some cases. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Alloantigen-dependent factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alloantigen independent factors contribute to decreased graft survival. Such factors include inadequate renal mass, prior and ongoing tissue injury, noncompliance, posttransplant hypertension, hyperlipidemia, a more marginal kidney, calcineurin toxicity, cytomegalovirus seropositivity, and recurrent or de novo glomerular disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Alloantigen independent factors'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/1\">",
"      Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/2\">",
"      Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/3\">",
"      Kasiske BL, Gaston RS, Gourishankar S, et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005; 5:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/4\">",
"      Higgins RS, Fishman JA. Disparities in solid organ transplantation for ethnic minorities: facts and solutions. Am J Transplant 2006; 6:2556.",
"     </a>",
"    </li>",
"    <li>",
"     Cecka, JM. The UNOS Scientific Renal Transplant Registry. In: Clinical Transplants 1996, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles 1997, p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/6\">",
"      Isaacs RB, Nock SL, Spencer CE, et al. Racial disparities in renal transplant outcomes. Am J Kidney Dis 1999; 34:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/7\">",
"      Kasiske BL, Chakkera H. Successful renal transplantation in American Indians. Transplantation 1998; 66:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/8\">",
"      Chakkera HA, O'Hare AM, Johansen KL, et al. Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs. J Am Soc Nephrol 2005; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/9\">",
"      Pallet N, Thervet E, Alberti C, et al. Kidney transplant in black recipients: are African Europeans different from African Americans? Am J Transplant 2005; 5:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/10\">",
"      Goldfarb-Rumyantzev AS, Koford JK, Baird BC, et al. Role of socioeconomic status in kidney transplant outcome. Clin J Am Soc Nephrol 2006; 1:313.",
"     </a>",
"    </li>",
"    <li>",
"     Terasaki, PI, Cecka, JM, Gjertson, DW, et al. Risk rate and long-term kidney transplant survival. In: Clinical Transplants 1996, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles 1997, p. 443.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/12\">",
"      Prommool S, Jhangri GS, Cockfield SM, Halloran PF. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000; 11:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/13\">",
"      Quiroga I, McShane P, Koo DD, et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006; 21:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/14\">",
"      Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/15\">",
"      Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 2005; 5:843.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ustransplant.org (Accessed February, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/17\">",
"      Rigden S, Mehls O, Gellert R. Factors influencing second renal allograft survival. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 1999; 14:566.",
"     </a>",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/SharedContentDocuments/KidneyConceptDocument.PDF.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/19\">",
"      Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation 2009; 88:231.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.optn.org (Accessed February, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/21\">",
"      Sellers MT, Velidedeoglu E, Bloom RD, et al. Expanded-criteria donor kidneys: a single-center clinical and short-term financial analysis--cause for concern in retransplantation. Transplantation 2004; 78:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/22\">",
"      Woo YM, Gill JS, Johnson N, et al. The advanced age deceased kidney donor: current outcomes and future opportunities. Kidney Int 2005; 67:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/23\">",
"      Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU. The broad spectrum of quality in deceased donor kidneys. Am J Transplant 2005; 5:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/24\">",
"      Ugarte R, Kraus E, Montgomery RA, et al. Excellent outcomes after transplantation of deceased donor kidneys with high terminal creatinine and mild pathologic lesions. Transplantation 2005; 80:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/25\">",
"      Remuzzi G, Cravedi P, Perna A, et al. Long-term outcome of renal transplantation from older donors. N Engl J Med 2006; 354:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/26\">",
"      Bernat JL, D'Alessandro AM, Port FK, et al. Report of a National Conference on Donation after cardiac death. Am J Transplant 2006; 6:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/27\">",
"      Punch JD, Hayes DH, LaPorte FB, et al. Organ donation and utilization in the United States, 1996-2005. Am J Transplant 2007; 7:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/28\">",
"      Tojimbara T, Fuchinoue S, Iwadoh K, et al. Improved outcomes of renal transplantation from cardiac death donors: a 30-year single center experience. Am J Transplant 2007; 7:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/29\">",
"      Summers DM, Johnson RJ, Hudson A, et al. Effect of donor age and cold storage time on outcome in recipients of kidneys donated after circulatory death in the UK: a cohort study. Lancet 2013; 381:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/30\">",
"      Sohrabi S, Navarro AP, Wilson C, et al. Donation after cardiac death kidneys with low severity pre-arrest acute renal failure. Am J Transplant 2007; 7:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/31\">",
"      Snoeijs MG, Schaefer S, Christiaans MH, et al. Kidney transplantation using elderly non-heart-beating donors: a single-center experience. Am J Transplant 2006; 6:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/32\">",
"      Kim SJ, Schaubel DE, Jeffery JR, Fenton SS. Centre-specific variation in renal transplant outcomes in Canada. Nephrol Dial Transplant 2004; 19:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/33\">",
"      Evans RW, Manninen DL, Dong F. The center effect in kidney transplantation. Transplant Proc 1991; 23:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/34\">",
"      Taylor RM, Ting A, Briggs JD. Renal transplantation in the United Kingdom and Ireland--the centre effect. Lancet 1985; 1:798.",
"     </a>",
"    </li>",
"    <li>",
"     Cho, YW, Cecka, JM. Organ procurement organization and transplant center effects on cadaveric renal transplant outcomes. In: Clinical Transplants 1996, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles, 1997, p. 427.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/36\">",
"      Watson CJ, Johnson RJ, Birch R, et al. A simplified donor risk index for predicting outcome after deceased donor kidney transplantation. Transplantation 2012; 93:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/37\">",
"      Ojo AO, Leichtman AB, Punch JD, et al. Impact of pre-existing donor hypertension and diabetes mellitus on cadaveric renal transplant outcomes. Am J Kidney Dis 2000; 36:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/38\">",
"      Fellstr&ouml;m B, Holdaas H, Jardine AG, et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation 2005; 79:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/39\">",
"      He X, Johnston A. Risk factors for allograft failure in United kingdom renal transplant recipients treated with cyclosporine A. Transplantation 2005; 79:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/40\">",
"      Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/41\">",
"      Salvadori M, Rosati A, Bock A, et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation 2006; 81:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/42\">",
"      Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/43\">",
"      Matas AJ, Gillingham KJ, Humar A, et al. Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. Transplantation 2000; 69:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/44\">",
"      Delmonico FL. Analyzing risk factors of renal transplant outcome. Transplantation 2000; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/45\">",
"      Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/46\">",
"      Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/47\">",
"      Pallardo Mateu, LM, Sancho Calabuig, A, Capdevilla Plaza, L, Franco Esteve, A. Nephrol Dial 2004; 19(Suppl 3):iii38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/48\">",
"      Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/49\">",
"      Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/50\">",
"      Opelz G. The benefit of exchanging donor kidneys among transplant centers. N Engl J Med 1988; 318:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/51\">",
"      Giblin L, O'Kelly P, Little D, et al. A comparison of long-term graft survival rates between the first and second donor kidney transplanted--the effect of a longer cold ischaemic time for the second kidney. Am J Transplant 2005; 5:1071.",
"     </a>",
"    </li>",
"    <li>",
"     Cecka, JM. Living donor transplants. In: In: Clinical Transplants 1995, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles, 1996, pp. 363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/53\">",
"      Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/54\">",
"      Humar A, Durand B, Gillingham K, et al. Living unrelated donors in kidney transplants: better long-term results than with non-HLA-identical living related donors? Transplantation 2000; 69:1942.",
"     </a>",
"    </li>",
"    <li>",
"     Cecka, JM, Cho, L. Sensitization.In: Clinical Transplants 1988, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles 1989, p. 365.",
"    </li>",
"    <li>",
"     file://www.ustransplant.org (Accessed 2/10).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/57\">",
"      Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/58\">",
"      Opelz G, Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/59\">",
"      Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/60\">",
"      Bryan CF, Mitchell SI, Lin HM, et al. Influence of the Rh (D) blood group system on graft survival in renal transplantation. Transplantation 1998; 65:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/61\">",
"      Escofet X, Osman H, Griffiths DF, et al. The presence of glomerular sclerosis at time zero has a significant impact on function after cadaveric renal transplantation. Transplantation 2003; 75:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/62\">",
"      Tullius SG, Volk HD, Neuhaus P. Transplantation of organs from marginal donors. Transplantation 2001; 72:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/63\">",
"      Ponticelli C, Villa M, Cesana B, et al. Risk factors for late kidney allograft failure. Kidney Int 2002; 62:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/64\">",
"      Lu CY, Penfield JG, Kielar ML, et al. Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney Int 1999; 55:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/65\">",
"      Pratschke, J, Vok, HD. Brain death-associated ischemia and reperfusion injury. Curr Opin Organ Transplant 2004; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/66\">",
"      Novitzky D, Rose AG, Cooper DK. Injury of myocardial conduction tissue and coronary artery smooth muscle following brain death in the baboon. Transplantation 1988; 45:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/67\">",
"      Stokes KY, Abdih HK, Kelly CJ, et al. Thermotolerance attenuates ischemia-reperfusion induced renal injury and increased expression of ICAM-1. Transplantation 1996; 62:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/68\">",
"      van der Hoeven JA, Molema G, Ter Horst GJ, et al. Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. Kidney Int 2003; 64:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/69\">",
"      Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 1995; 333:1111.",
"     </a>",
"    </li>",
"    <li>",
"     Lim, EC, Terasaki, PI, eds. Early graft function. Los Angeles: UCLA Tissue Typing Lab., 1991. In: Clinical Transplants 1990, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/71\">",
"      Opelz G, D&ouml;hler B. Multicenter analysis of kidney preservation. Transplantation 2007; 83:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/72\">",
"      Troppmann C, Gillingham KJ, Gruessner RW, et al. Delayed graft function in the absence of rejection has no long-term impact. A study of cadaver kidney recipients with good graft function at 1 year after transplantation. Transplantation 1996; 61:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/73\">",
"      Morris PJ, Johnson RJ, Fuggle SV, et al. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Lancet 1999; 354:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/74\">",
"      Wigmore SJ, Seeney FM, Pleass HC, et al. Kidney damage during organ retrieval: data from UK National Transplant Database. Kidney Advisory Group. Lancet 1999; 354:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/75\">",
"      Giral-Classe M, Hourmant M, Cantarovich D, et al. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 1998; 54:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/76\">",
"      Peters TG, Shaver TR, Ames JE 4th, et al. Cold ischemia and outcome in 17,937 cadaveric kidney transplants. Transplantation 1995; 59:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/77\">",
"      Schnuelle P, Lorenz D, Mueller A, et al. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney Int 1999; 56:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/78\">",
"      Bryan CF, Luger AM, Martinez J, et al. Cold ischemia time: an independent predictor of increased HLA class I antibody production after rejection of a primary cadaveric renal allograft. Transplantation 2001; 71:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/79\">",
"      Chandraker A, Takada M, Nadeau KC, et al. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int 1997; 52:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/80\">",
"      Waldman WJ, Knight DA. Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cytomegalovirus-activated T cells. Am J Pathol 1996; 148:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/81\">",
"      Brenner BM, Milford EL. Nephron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis 1993; 21:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/82\">",
"      de Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/83\">",
"      Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J Am Soc Nephrol 1992; 3:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/84\">",
"      Kim YS, Moon JI, Kim DK, et al. Ratio of donor kidney weight to recipient bodyweight as an index of graft function. Lancet 2001; 357:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/85\">",
"      Moreso F, Ser&oacute;n D, Anunciada AI, et al. Recipient body surface area as a predictor of posttransplant renal allograft evolution. Transplantation 1998; 65:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/86\">",
"      Kasiske BL, Snyder JJ, Gilbertson D. Inadequate donor size in cadaver kidney transplantation. J Am Soc Nephrol 2002; 13:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/87\">",
"      Giral M, Nguyen JM, Karam G, et al. Impact of graft mass on the clinical outcome of kidney transplants. J Am Soc Nephrol 2005; 16:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/88\">",
"      Oh CK, Jeon KO, Kim HJ, et al. Metabolic demand and renal mass supply affecting the early graft function after living donor kidney transplantation. Kidney Int 2005; 67:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/89\">",
"      Nishimura Y, Tomikawa S, Beck Y, et al. Kidney graft weight as an important risk factor for long-term graft survival. Transplant Proc 1998; 30:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/90\">",
"      Giral M, Foucher Y, Karam G, et al. Kidney and recipient weight incompatibility reduces long-term graft survival. J Am Soc Nephrol 2010; 21:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/91\">",
"      Smith AY, Van Buren CT, Lewis RM, et al. Factors determining renal transplant outcome at the University of Texas at Houston. Clin Transpl 1987; :155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/92\">",
"      Burke G, Esquenazi V, Gharagozloo H, et al. Long-term results of kidney transplantation at the University of Miami. Clin Transpl 1989; :215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/93\">",
"      Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/94\">",
"      Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/95\">",
"      Sanders CE Jr, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl 1995; 52:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/96\">",
"      Cheigh JS, Haschemeyer RH, Wang JC, et al. Hypertension in kidney transplant recipients. Effect on long-term renal allograft survival. Am J Hypertens 1989; 2:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/97\">",
"      Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/98\">",
"      Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/99\">",
"      Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000; 283:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/100\">",
"      Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/101\">",
"      Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/102\">",
"      Andresdottir MB, Hoitsma AJ, Assmann KJ, et al. The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. Transplantation 1999; 68:623.",
"     </a>",
"    </li>",
"    <li>",
"     2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD. file://www.ustransplant.org/annual_reports/current/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/104\">",
"      Doshi MD, Hunsicker LG. Short- and long-term outcomes with the use of kidneys and livers donated after cardiac death. Am J Transplant 2007; 7:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/105\">",
"      Weber M, Dindo D, Demartines N, et al. Kidney transplantation from donors without a heartbeat. N Engl J Med 2002; 347:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/106\">",
"      Droupy S, Blanchet P, Eschw&egrave;ge P, et al. Long-term results of renal transplantation using kidneys harvested from non-heartbeating donors: a 15-year experience. J Urol 2003; 169:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/107\">",
"      Cooper JT, Chin LT, Krieger NR, et al. Donation after cardiac death: the university of wisconsin experience with renal transplantation. Am J Transplant 2004; 4:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/108\">",
"      Keizer KM, de Fijter JW, Haase-Kromwijk BJ, Weimar W. Non-heart-beating donor kidneys in the Netherlands: allocation and outcome of transplantation. Transplantation 2005; 79:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/109\">",
"      Moore J, McKnight AJ, Simmonds MJ, et al. Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. JAMA 2010; 303:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/110\">",
"      Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/111\">",
"      Brown KM, Kondeatis E, Vaughan RW, et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 2006; 354:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/112\">",
"      Varagunam M, Yaqoob MM, D&ouml;hler B, Opelz G. C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med 2009; 360:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/113\">",
"      Radermacher J, Mengel M, Ellis S, et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003; 349:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/114\">",
"      Marsden PA. Predicting outcomes after renal transplantation--new tools and old tools. N Engl J Med 2003; 349:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/115\">",
"      Winkelmayer WC, Kramar R, Curhan GC, et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol 2005; 16:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/116\">",
"      Bostom AG, Carpenter MA, Hunsicker L, et al. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis 2009; 53:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/117\">",
"      Halimi JM, Buchler M, Al-Najjar A, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007; 7:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/53/14170/abstract/118\">",
"      Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005; 5:2281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7302 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-854D70C629-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14170=[""].join("\n");
var outline_f13_53_14170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18182802\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SHORT TERM SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Delayed allograft function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HLA antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type of kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H567502624\">",
"      - Standard criteria donor kidneys",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H567502638\">",
"      - Expanded criteria donor kidneys",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H567502631\">",
"      - Donation after cardiac death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Center effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H567502790\">",
"      Donor age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Donor illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dialysis and preemptive transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LONG-TERM SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Alloantigen-dependent factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Episodes of acute rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - HLA matching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Alloantigen independent factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tissue injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Inadequate renal mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Drug noncompliance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Posttransplant hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Recurrent or de novo glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Type of kidney donor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Additional factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14813848\">",
"      OPTOMIZING OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18182802\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7302\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7302|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/15/4347\" title=\"table 1\">",
"      Factors used to calculate KDPI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/437?source=related_link\">",
"      Deceased and living donor renal allograft recovery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=related_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=related_link\">",
"      Organ sharing in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36517?source=related_link\">",
"      Psychiatric aspects of organ transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_53_14171="Contraindication neobladder";
var content_f13_53_14171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absolute and relative contraindications for continent cutaneous/orthotopic neobladder urinary diversions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired renal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired hepatic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical or mental impairment to perform self catheterization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive apical urethral margin (for neobladder)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unmotivated patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated comorbid conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advanced age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need for adjuvant chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior pelvic radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensive local disease with soft tissue extension and high risk of local recurrence",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14171=[""].join("\n");
var outline_f13_53_14171=null;
var title_f13_53_14172="Obstetric complic by BMI";
var content_f13_53_14172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Obstetric complications by maternal BMI",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Outcome",
"      </td>",
"      <td class=\"subtitle1\">",
"       Control (n=13,752), percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Obese (n=1,473), percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Morbidly obese (n=877), percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gestational hypertension",
"      </td>",
"      <td>",
"       4.8",
"      </td>",
"      <td>",
"       10.2",
"      </td>",
"      <td>",
"       12.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preeclampsia",
"      </td>",
"      <td>",
"       2.1",
"      </td>",
"      <td>",
"       3.0",
"      </td>",
"      <td>",
"       6.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gestational diabetes",
"      </td>",
"      <td>",
"       2.3",
"      </td>",
"      <td>",
"       6.3",
"      </td>",
"      <td>",
"       9.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preterm premature rupture of membranes",
"      </td>",
"      <td>",
"       1.7",
"      </td>",
"      <td>",
"       2.1",
"      </td>",
"      <td>",
"       2.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preterm delivery",
"      </td>",
"      <td>",
"       3.3",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"      <td>",
"       5.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fetal growth restriction",
"      </td>",
"      <td>",
"       1.1",
"      </td>",
"      <td>",
"       1.0",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birth weight &gt;4000 g",
"      </td>",
"      <td>",
"       8.3",
"      </td>",
"      <td>",
"       13.3",
"      </td>",
"      <td>",
"       14.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birth weight &gt;4500 g",
"      </td>",
"      <td>",
"       1.0",
"      </td>",
"      <td>",
"       2.1",
"      </td>",
"      <td>",
"       2.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Placenta previa",
"      </td>",
"      <td>",
"       0.6",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Placental abruption",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Operative vaginal delivery",
"      </td>",
"      <td>",
"       10.5",
"      </td>",
"      <td>",
"       8.5",
"      </td>",
"      <td>",
"       11.1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Weiss, JL, Malone, FD, Emig, D, et al. Obesity, obstetric complications and cesarean delivery rate: A population- based screening study. Am J Obstet Gynecol 2004; 190: 1091.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14172=[""].join("\n");
var outline_f13_53_14172=null;
var title_f13_53_14173="Lactate threshold";
var content_f13_53_14173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lactate threshold according to exercise intensity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 356px; background-image: url(data:image/gif;base64,R0lGODlhgwFkAdUAAP///4CAgAAAAEBAQMDAwP8QEBAQEKCgoNDQ0CAgIPDw8P/w8FBQUHBwcODg4GBgYP9AQP+AgDAwMP/Q0P/AwJCQkLCwsP/g4P+goP9gYP+QkP9QUP8gIP8wMP+wsP8AAP9wcAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACDAWQBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6BYCARECAEBCKGqq5EOBwYCQxYCCQkCFqy5uocBAr5DEgIICAISAASnycqnpLvOz3G/QtK/yMvKAwHQ29xp0gDUsUun3eXmYN+wCgoCBkzk5/HyVA4EvgQOAA8CpwIP79rmCRw4zpcvbQoY+GKgACDBhxC5wItIsWKUiRYzajyCcaNHjR0/iowYcqRJgSVPqjSXcqVLaC1fyswVc6ZNUDVv6tyUc6dP/0s9fwqNFHSoUUZFjyrlFXCpU0hJn0r1E3Wq1TxVr2qlk3Wr1zddv4pVE3as2TJlz6oFk3at2y1t38q1EncuIQ8euFm7diqbXU4cMOjlm8zv30waOkCse9jPggIUFjdtTCkCBJKTKUd6PAGzZkoZMlBk/PnOhQ8XRmcuzWgDiIqkWc+hUGAB7NWyEUGIYDF27jcUONi+/XtR4Iy+i6/BwAEkbuWAFnDIi/w5dD+WNya/XuZxZOfcB0XY4HF7+DCnU2u3fv5O6I/m23e5UED9evl9douMjz8L7eHlsdcfHPrtJ+CAbTAXzwG2GHCgEPwhSMVx5hCTAAG2pOKQhHRgoP/YOcQYYMEABuSzIYdxeCdPLwcNsRdfhqEIR3bxEGAAA6/cIsSL18QoYxsqxtNLAwA0wE8TEf64xHvyOADLAO2YOM6DSoKRnkAOVBDAAQ0hSWWVXmTw2kpJglnEfy6VaeYQBZL55ZpYoJnmm3BaQeGcdZKhoExqmjndTH1WSSOfdOYJRZCEGgrGoIkqOl99NwUqI5M2ScrhlZEW6qgSbVaq6aZHyJkpqFl06impV3jQnE+WDninTq3ityern6KK6E6xtscorrWCeiuvqE4BgmhD5codpkIZex2lK/G4jI/BMiFqs4T11auipv6kbHHTJnttnh0IptS2uc16FLmyvWr/FLqlaXCZU+xq9uu635q567n1VklfZ0/F2xizS/n7F7Lw5vvjBrxNJfBc3VaoIRkLy5WtOQMMYEbEbqkKoDwVX2wwh+puUw8BJBMggcVofYygud2waJAAKEOscn/SfWfOARXnPACRKUdbxL1SYWzWvEHPLB8I5MkjAZdrCC0WweYEY8ADD3vssxAAg/gALAlU0OUUIzvhtFcT1PaQAjj78oCUTigA5TdTXj0xlg0Y0MwTUFYAANtKjK1VwxB93YQDtDwwgN47VhsAtKBCoAFBJUdetRP2JBAALM04i43R17Esz8sGxfyEPRb38qDfU0lH3UB8HTCFAQYkJIDrJ4IK//RABEwOxQEG/eMlqlAPhAAsxQgOhQK5P4H6U3PPU0sAdfsuM6kemE2RAM0sbvWm0olLUQIMEGCBBNKPsbxStw/Euy8G6M4W57Kdxq9FplTAtxjnGwXBmBmNQrL7X8ifUKq3MYooJHTby1P3NlKMZNBueoZK30N2Rhb4aUZ+HrFRzngGwTq55iPE84Xo8GfBxgCOIgbg4BkEqJOQWaQBAygZAL3AQptIMCJvE2ECwbSvkRxAGQ80Xwnt8sHG1PAlJ7SIArR0iiCScE0u1IgtENgzMN2wIgII3/92KCP62GwkDSgfF1G0AWKdZH06rOKPkqiRdmxwjBLiwONWYrkKKv8pAh9aSQMs10Q49seLL8khzLagucIM8SxllIn/tqiFQlpLRmy0yxFFIsffTNIjiSnOJTVCNM1sMiNZUyTT1NifSJ7EHg4yXgAP6ZUOzNEnyGAcDVmplUzuxAIBcAAq/HidTurxHgwQYxg+GZFQvmRqEoglL5VjSpNgL4aGW2ZxOpCwnQxAAuATAOI6eB4NrMonw/OFBFT5Pvn4cibJWyEtn5KBpP2kAbTTkjRZQxv76AR55CMZA0Y4zHUuhZpCsQfohFnO8HhzKLpMQDYC4LV5ygsyR0HA/bipnHYqJUdppOhvymZPodQCZlNzaGOap5NbxCKMIv2L54SCPQkEYJ//Vfjh3eKmnHPqhHwsUiEUZnGk3ykHaVapwDajoADY9bR2suHoU+ApBHlKgQEuPSpNf0PSe5rsAfrkJxNmUYF9rC1x1ZKlZlYaUND5Qwoua9ExFCfWxthUJwldaEOpYDqx+VMnIHiXVCzgOuSR0wk4c2ISiLmNCaDGKhJgAAAUkACCrjI3VWVp9rT6WNYwp4BOMQDiGKBYUlLmMaubyj4kEAzBFvQzed2KAvaRQnWWxrAd5RBhdxFZoyBgnxXTaT8/c1mvBIOKGp2L6r4yu1g8gJWzZcUVlYK9C8EwpV8JnlUst48sQtcrtVXKMBLCkOtqRWNrOYBpK2uXsnnvLB3z/6xbzPuW9Ab3LAvoAP++wiOFevcp8TWjWNKaUSHOJQN5HIuzxjtLuQAYs2tK7iY0YD1FKTgTGCjA/Bx814wY9osUVgt7SfXgSjzmlaDq8CTyGy0RSwIC7jSTIxdXYYgcuE4rbutTQNABBG/KxI6I8ISDhWNGVG/HPG7xPDZ8NQD0OBFELvKRDxHf+SpZyOYgcZGJsORCAHjKRajyIF6M5SFoORAMtvHVvvwHHXc5y1CGxoXPjOalJJnNRk7zLj4M5zYbRcp19rKcc4HiPNtZKFz2M4T2rAoai5nNZL6DmQVNZUJ/4seM/vNN3hzpRM+B0pV29CaarGRYGIDAkn4Jnv99xoAGGEkAEzWCpeFw5TNDaaaD1TQmAj1lwiXArjMJ85kdIIH2uYitsq7EorE8vARULcbBnsSazwy60yU7EpgeszJgjYRVp4HOkfapSUad7b492xF97ra2RUJrccfaJIZuAgE6m+mRDDsJaRMH5aidBgpWAQEDADUA8O1Ee0vmIxOIgISVgLYpwo0JB0c4ZQEAJSbYIyCDrMLDlzBxIkT83xaZgAY2UIACQOC8RVDA5cwKBbjhbAAMwMXeYJhy3lmuHrjVG4b4QYp170xw+/ALzCowgAc05IdZysfJEWeBfWLVHqY2jAJgSLVj9HRxOVdNRDTO8QJsQANAJoIDqmv/Vpjp7OtOhFupA2ALBxTVQYYzkgEGYIrjQkm8TzrALEptXWDQwmLitMU/oIQ5IzVAIRXgHQNeGgCBkmh2AOh1AHpdjyMZafAXf4i1rUD1jl8960fYWtfvEbnO8w1uuhyALQhQAcTvDRwoWyJUj9RwACjkFLYgQsUHyQ6LQalLBuDjzhvouonPAhUCIBJXJ577aSxcSN/GQ+WtjnUqFL3rJZe3k5a2D2Rgz+Io67VQWS8OKClD9j2N+CBbDw4+bsnIb2vAxB++fpofSfzHP8fkm7D8y2sBbb9NuBIOwowsEuDVxJBMB6BYtIAPBWgk2gAlFoAApRc+FlA+9pByqGd8/wwnb69HAD9UAeoneO2nDbm3bsIwcQrIO/HHEsn3BvXXfGCQUPLWBKCjD+0QDKQwPi3CIgiwPt4HABYAC3pDdgtRBHw3gRNIfqvlaQFgAVPEEB24b8GQAL13JAhgC1BSguUwf0SQgpgHBgjwV4h2gmaAhebWNF4YBmAYhm2gZWVohmAxhlZwARTgAeNheSqohnLwSW4Ih5YBAQXwAR63G3NIh1zBhkNwhxGQh3vYh4XoARQQW4B4BwtDiIbIhxCwGxGgiIzYiFSRZpA4iYc4iYm4iJjYCIFCAZGIiJUIiqFICaN4ipeYipVgha7YBcgWixoxi7ToJreIi7l4ErC4i/9P5Isj0YvASF7DeB/FGCDHiIzJCB7LWB3N6IzPSBzRKHXT6BnViHHXSBDCmI1oJYjc6Ije+I11sI3iiGvluCLheI5egDZbwoWhpo6ZEAxQYgzjBo+YMHeupyNIZY9AcSR1tY/8qIr+KFXnFpCYUHpEYiSIE2MLpTgO+ZAQGZESOZEUWZEWeZEYmZEauZEcuZH0Nge2NnMmwpAdKZEVU5Im2ZAo6ZAnuZIQ2ZIuGVYqGZOEAZM02SMnyCC0oG96lgaS8pMVFiiWIpTpCJC/iAZAKYY+GZT+lFxEaUdLqZRIyZRRKYpNeVdJCZWupZX3tQdPWZVTKZVbCZZdqQdfGZb/ZDmWZUkXV+kIZ6mWa1kFbwmX72UIc6ledXmUcUlXbWmVaYmX/sWVgBmYdIkId5mXp4WWhYmYBdYIJJMGjwmZHykGkSmZlqkGlWkGmWmQnNmZngkR9ZBqjTAKM6SF+CASYTMQXOdYYEA6aHBAZ2UGIaRbYsBYBCkGL2gGbmMQmgk6k/kHAZh4wmAGb0OFcGEBOzicZYBV6/OaalUG/EdLeXN6ZaBL0OMLpUkVA8lKDBh5ZxAM2ckFDjALxpkFc3ebYXAQc0UGtmY4Q4UW3kkIdfWPZeCakBmf+OMLKkcGRdUPtLR2tpAA7khItDByv9kFRXV9hrmdZ2CfZ7CD46QG/+AJn6K3k2kgg/U5SPQJMfg5CME5ob1ZnllQeglgAadJBgigfskZnllgDVN4oFqQohgIC6LZBbAjOzypBU6ioImwmmcgSDCqBc1WBsRgELSZn9z5MjmqBWjEml4QdYwQmmiwSAQwoIQUOTXKBchzomggpbpJMlaKoOmkmVX6mWZ6pmiapmq6pmzapm76pnAap3KKmZGTBfw2p3uQm1egS0GqBOSHp17AeaSgJQ1BqAAwdBByAKawWDx3OHy6WDDkFyKHcvspBEt3kjNXeEVSMU2Hfg1wfodaMe8JqEbAf0/4ALyjN34HeOBAPBVoanZzJAngIHuUeA4CokIwq9DjhOpxBwCWUze39ni9YDGrqk2kmgQvgzKldyNCkHv9gHf0SAy+03geODW5RAzZsA+TATvHlQ/kRwAwBAvlR4HOOqzHigQHRzimV6B9FHEV53TacFsNQoLJMFPyGiWtN3c0KISDxK6geq5FEJ2L1WskkgoX+ENCCACwg5zJxHoH8H/CADsPG3hEkG8Qi2+3YAr8gISxEAx8NUgHW5Rq+ILVV1TjVITtoA0Xd1siNHEH5IT79rKV+rKuk5xe04SxF4UwQ3ua5yAAmwjiY31H+rOHsD5TE6ZEm7RKu7RM27RO+7RQG7VSO7VUW7VvEAQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At low to moderate exercise intensity, lactate production is matched by clearance, and blood lactate concentration increases only slightly. As exercise intensity increases (between stages 3 and 4), lactate production exceeds clearance, and lactate concentration begins to increase exponentially. The lactate threshold occurs just before the exponential rise in an individual's potential for high-level endurance performance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14173=[""].join("\n");
var outline_f13_53_14173=null;
var title_f13_53_14174="Higher BNP predicts death in non ST ACS";
var content_f13_53_14174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Levels of brain natriuretic peptide predict mortality in patients with an acute coronary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 2525 patients, the level of brain natriuretic peptide (BNP) predicts 10-month mortality in subgroups with an ST segment elevation and non-ST segment elevation myocardial infarction and unstable angina. P values are for the trend within each subgroup.",
"    <div class=\"footnotes\">",
"     * p = 0.02.",
"     <br>",
"      &bull; p &lt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from de Lemos JA, Morrow DA, Bentley JH, et al. N Engl J Med 2001; 345:1014.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14174=[""].join("\n");
var outline_f13_53_14174=null;
var title_f13_53_14175="Actions of cobalamin";
var content_f13_53_14175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Role of cobalamin (vitamin B12) in homocysteine and methylmalonic acid metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 364px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Role of cobalamin in homocysteine and methylmalonic acid metabolism. Panel A - Methylcobalamin is a cofactor in the synthesis of methionine from homocysteine. Panel B - Adenosylcobalamin is a cofactor in the synthesis of succinyl-CoA from methylmalonyl-CoA. Tetrahydrofolate (THF) participates in homocysteine but not methylmalonic acid (MMA) metabolism. Thus, cobalamin deficiency is characterized by elevations in the serum levels of both homocysteine and MMA, while only homocysteine levels are elevated in folate deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Tefferi, A, Pruthi, RK. The Biochemical Basis of Cobalamin Deficiency. Mayo Clin Proc 1994; 69:181",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_53_14175=[""].join("\n");
var outline_f13_53_14175=null;
